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I have spoke with the tongue of angels 
I have held the hand of a devil 
It was warm in the night 
I was cold as a stone. 
 
—Bono, ”I Still Haven’t Found What I’m Looking For” 
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ABSTRACT 
The act of completed suicide is a complex phenomenon associated with numerous 
identified individual and combined risk factors. Mental illness and related disorders confer 
among the highest risks of completed suicide and have consequently been targeted through 
pharmacological interventions. However, psychotropic medications and their possible 
effects on completed suicide have proved notoriously difficult to study. Nonetheless, it is of 
great importance to further investigate these classes of medications and their role in the 
suicidal process.  
 
The thesis focuses on toxicological verification of psychotropic medication among 
individuals who have committed suicide or died of other causes in Sweden.  We have 
investigated the potential role of selective serotonin re-uptake inhibitors in the choice of 
suicide method and demonstrated the level of adherence to and recreational use of the most 
commonly prescribed non-addictive psychotropic medications in the Swedish population. 
In yet-to-be-published Study III, we have examined purchasing patterns for psychotropic 
medications during the year prior to death, as well as the impact of the level of medication 
adherence upon the risk of completed suicide. 
 
All studies are based on Swedish national registry data from a period of nearly ten years 
(2005-2014).  Full coverage on dispensed prescriptions, results of medico-legal autopsies, 
causes of death and diagnoses from inpatient care have been used to operationalize 
investigated exposures and outcomes and facilitate adjustments for confounders in two 
case-control studies and one methodological study. By the use of the prescription-based 
algorithm PRE2DUP, purchases of psychotropic medications and calculated lengths of use 
were compared with forensic-toxicological findings as a measure of adherence. Logistic 
regression and Cohen’s kappa have been the principal statistical methods used. A new 
measure of continued need of treatment – the dispensation ratio (the ratio of initiated and 
discontinued prescriptions) – was also developed. 
 
Two of the main findings are that selective serotonin re-uptake inhibitors are associated 
with violent completed suicide during early treatment among elderly subjects and that 
presence of other substances (including other medications and illegal drugs) is an important 
confounder of associations between treatment with selective serotonin re-uptake inhibitors 
and choice of suicide method. Overall, rates of adherence in the Swedish general population 
to psychotropic medication, as reflected by therapeutic blood concentrations at forensic 
autopsy, are good. Biochemically verified incomplete adherence to antipsychotics, as 
shown in Study III, is associated with a markedly increased risk of completed suicide. The 
corresponding effect size for antidepressants was shown to be smaller and no longer 
statistically significant after adjustments for the dispensation ratio. 
 
Forensic-toxicological data are largely conservative biochemically verified measures of the 
possible impact of psychotropic medication upon the risk of death. By combining such data 
with national registry data, we have revealed findings of great importance to further suicide 
prevention and, at the same time, demonstrated a public-health-oriented application of 
results from medico-legal autopsies, beyond their immediate use in forensic investigations. 
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1 INTRODUCTION 
1.1 BACKGROUND 
Suicide has throughout history evoked controversy and debate and been a topic of 
interdisciplinary research, including accounts of historical, philosophical and medical 
importance. A number of risk factors have over the years been identified for academic and 
practical clinical purposes to raise awareness and to identify individuals at risk and manage 
this risk. There exist a variety of suicide prevention strategies possessing different levels of 
evidence.1 Pharmacological alternatives for treatment of underlying psychiatric conditions 
have, furthermore, been suggested as cost-effective interventions in suicide prevention.2, 
However, there has also existed a parallel, long-standing debate about whether psychotropic 
medications actually do prevent suicide or whether they might even exert a prosuicidal 
effect.,3 Although randomized controlled drug trials have been adopted by the medical 
community since the 1940s, a number of important limitations have made such a study 
design unacceptable for use in the study of completed suicide.4 With increased accessibility 
to electronic health records, including prescription history, real-world data have been possible 
to use in observational studies. However, despite numerous large, population-based studies 
investigating antidepressant medications’ prosuicidal and antisuicidal properties, results 
regarding their overall effect on suicide risk have remained inconclusive.5 Protective effects 
for completed suicide have, nevertheless, been found regarding the use of lithium and 
clozapine, as well as in single studies of antidepressants with a prerequisite of continuous 
drug use.6,7 There exist, at the same time, discrepancies between studies with regard to how 
continuous drug use can be operationalized, as well as with regard to complete information 
on concomitant use of other substances potentially affecting the intended effect of 
psychotropic medications. This gap of uncertainty can be filled by the use of forensic 
toxicology, as it offers direct biological measures of substances present in the body. 
Furthermore, as completed suicide is only possible to study post factum the use of 
postmortem forensics is of particular value.  
This thesis is centered on Swedish population-based registry studies that, through the use of 
forensic-toxicological findings, operationalize biological verification of exposure to 
psychotropic medications with an aim to further evaluate and develop tools for the 
application of real-world data in the assessment of the influence of adherence to prescribed 
medications on completed suicide.  
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1.2 DEFINITION OF SUICIDE 
The term suicide stems from the Latin roots suus (oneself) and caedere (to kill) and was first 
used by Sir Thomas Browne in 1643.8 There is a lack of consistency in the literature 
regarding the use of the term, with intended meanings including suicidal ideation, suicide 
attempt, and the completed act of suicide. The intention of this thesis has been to as far as 
possible investigate completed suicide. Thus, if not stated otherwise, the term suicide will 
refer to completed suicide, which is defined by the World Health Organization (WHO) as 
“the act of killing oneself deliberately initiated and performed by the person concerned in the 
full knowledge or expectation of its fatal outcome”. 9   
1.3 A HISTORICAL VIEW OF SUICIDE AND TOXICOLOGY 
One of the earliest known written descriptions of depressive illness and suicidal ideation 
stems from an Egyptian text known as “Tired of Life” or the “Dialogue of Man and his Ba” 
by an unknown author from circa 2000 BC.10 Ebers Papyrus (Egypt, circa 1550 BC) is 
considered to be the first known written account describing naturally occurring toxic 
substances, such as opium, lead and hemlock. In ancient Greece, following Pythagoras, Plato 
condemned self-killing and advocated posthumous censure, including burial without honors. 
Later, the Cynics, as well as both Greek and Roman Stoics, adopted a more liberal stance. 
Around the time of death of Socrates in 4th century BC, the Greek philosopher and botanist 
Theophrastus catalogued descriptions of dangerous plants in De Historia Plantarum. In the 
Roman era, voluntaria mors – voluntary death – was closely coupled with explicit methods of 
suicide – modi moriendi – to ensure a dignified death.11 The physician Pedanius Discorides,  
who served under the emperor Nero, wrote, in the 1st century AD, De Materia Medica , 
which, apart from containing the first formal classification of poisons, is a major historical 
source on the use of medicine in antiquity.12  
In Islam, the Quran (632 AD), in surah 4:29, explicitly states, “And do not kill yourselves 
(nor kill one another)” 13; however, suicide in martyrdom – shahada – has by some groups 
been interpreted as a means of carrying out jihad. 14 The study and treatment of poisoning is 
found in the hadith, and by the 10th century, the science of toxicology was well established in 
Islamic countries (as illustrated by, for example, Ibn Wahshiyya’s Book of Poisons and 
Avicenna’s Canon of Medicine).15 In China, Confucius (who lived from 551 BC to 479 BC) 
took a positive stance on suicide; however, in later premodern China (i.e., the period between 
221 BC and 1800 AD), Confucianism regarded suicide as wrong, in that it violated 
expectations regarding filial piety.16 The oldest known writings on forensic medicine stems 
from 13th century China: in the Hsi Yuan Lu (“
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of Wrongs”), detailed systematic forensic accounts are presented regarding means by which 
one can distinguish suicides from homicides and accidents, as well as regarding methods by 
which one can detect “suicide by poisoning”. 17  
The development of the Christian doctrine of suicide prohibition followed St. Augustine’s 
publication of his interpretation and extension of the Fifth Commandment, “Thou shall not 
kill,” in 426 AD. This view of suicide as an unrepentable sin was further developed and 
defended by St. Thomas Aquinas in 1271.18 In the 16th century, Theophrastus von 
Hohenheim, or Paracelsus – who is credited as being the “Father of Toxicology” – 
formulated the maxim “the dose makes the poison” and reformed the role of chemistry in 
medicine.12 Decriminalization of attempting suicide began across Europe after the French 
Revolution at the end of the 18th century, and during the 19th century, psychiatry advanced 
into an autonomous discipline, with independent hospitals and asylums for treatment of 
mental illness and suicidality. Around the same time, Mathieu Orfila established the modern 
scientific foundation of forensic toxicology by systematically correlating chemical and 
biological properties of poisons. In addition, he refined existing analytical methods for 
toxicological detection, as well as creating several new methods.12 
During the 20th century, the first right-to-die organizations were formed in the 1930s, with 
physician-assisted suicide becoming available in Switzerland 1942. During this time, rapid 
advancements in toxicological detection and automation were seen in the forensic sciences, 
aided by concurrent broad advancements in analytical biochemistry. In the last hundred years, 
theoretical mass accuracy of toxicological detection have gone from parts per hundred (10−2) 
to parts per quadrillion (10−15) – results attainable at a fraction of previous times and costs.12 
Subsequent to the swift availability of Internet in the 21st century, the term cyberbullicide was 
coined in 2007 in reference to individuals taking their own life following harassment over the 
Internet.19 In response to live-streamed suicides, major platforms for social media have since 
developed artificial-intelligence algorithms for automatic screening of suicidality.  
1.4 EPIDEMIOLOGY 
In 2015, close to 800 000 people worldwide were estimated to have committed suicide, 
representing an annual global age-standardized suicide rate of 10.7 suicides per 100 000 
inhabitants and accounting for 1.4% of all deaths worldwide.20 Although reported suicide 
rates have declined globally since 1990, in 2013 self-harm rose from being the 16th to the 14th 
leading cause of global years of life lost.21 Age-wise suicide occurs most frequently among 
the elderly (70 years or older), and is the second-leading cause of death among people 
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between the ages of 15 and 29 years. The male-to-female suicide ratio is about 2:1 worldwide 
but varies between geographical regions, levels of income and age groups. In the Western 
world, the male-to-female ratio is between 3:1 and 4:1, whereas, in low-income and middle-
income countries, it is about 1.5:1.22 Bangladesh, China, Indonesia, Iraq and Pakistan have 
been the only countries to report suicide rates in women exceeding those in men.23 Violent 
suicide methods are world-wide more common than non-violent means – intoxications – and 
are predominantly used by men.24   
During the early 1970s, Sweden reported one of the highest suicide rates in the world, but 
since then, the country has had a steadily declining rate of registered completed suicides. The 
reported age-standardized rate of suicide in Sweden for both sexes in 2012 was, according to 
the WHO Mortality Database, on par with rates in Australia, Chile, Germany, Thailand, 
Uganda and the United States (age-standardized rate 11.6 to 13.7 suicides per 100 000 
inhabitants).23,25 The reduction in rates of completed suicide has been seen in both sexes and 
in all but the youngest age group. Among teenagers and younger adults (between the ages of 
15 and 24 years), suicide rates plateaued in the 1990s but have during the past decade showed 
a slight tendency to rise. The Swedish male-to-female-ratio has since 1980 lain between 2.2:1 
and 2.7:1.26 Among same-sex married couples, the risk of suicide has been estimated to be 
nearly three-fold higher than the risk among different-sex married couples.27  
 
Figure 1.1. Age-standardized suicide rates in Sweden compared to in other countries belonging to the 
Organization for Economic Co-operation and Development (total, per 100 000, 1965-2015). Source: OECD 
Health Statistics: Health status 
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1.5 ACKNOWLEDGED RISK FACTORS 
Recognized risk factors for completed suicide vary between sexes and across geographical 
regions and age groups, and have in some studies been identified as potentially consisting of 
more than 200 non-categorized variables.28 More broadly, they can be subdivided into 
acknowledged individual-level and societal-level factors, the main categories of which are 
described below.   
1.5.1 Individual-level risk factors 
1.5.1.1 Mental illness 
Meta-analyses have over the years investigated overall rates of total and specific psychiatric 
disorders in people who have committed suicide.29–33 Being diagnosed with any mental 
disorder, but also having had a history of psychiatric treatment, confers an increased risk of 
suicide in comparison to the general population.  A diagnosed mental disorder entails an 
increased risk not only of premature death by suicide, but also of all-cause mortality, which 
by estimates can be translated a reduction in life expectancy of between 10 and 20 years. The 
specific psychiatric diagnoses that are currently considered to carry the highest risks of 
completed suicide are anorexia nervosa, bipolar disorder, borderline personality disorder, 
major depressive disorder and schizophrenia.33 
1.5.1.2 Ideation and previous suicide attempt  
Expression of suicidal ideation and a previous suicide attempt have been considered to be 
among the strongest predictors for completed suicide,34–36 and severe lifetime suicidal 
ideation is probably the best predictor of completed suicide in the long term 37. Attempters of 
violent suicide have been shown to more likely repeat the attempt with a successively higher 
degree of lethality.38 Although ideation and a previous suicide attempt can, in part, contribute 
to the formal diagnosis of an affective disorder,39–41 they still elevate the risk of completed 
suicide in other psychiatric conditions, such as schizophrenia.42,43 Suicidal behavior in itself 
has been proposed as a separate diagnosis, and it has even been argued that it fulfills the 
diagnostic criteria for addiction.44,45 
1.5.1.3 Substance use disorder 
In the former Soviet Union and other countries worldwide, total population alcohol 
consumption has been shown to be strongly positively correlated with trends of national 
suicide rates.46,47  At the individual level, repeated cross-sectional studies have shown alcohol 
intoxication to be present in suicidal behavior and completed suicide.47,48 Moreover, although 
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there have been significant discrepancies between publications, the evidence from larger 
cohort and case-control studies is nonetheless ample, and alcohol use disorder is considered 
to be an important individual predictor of completed suicide.49 In substance use disorders 
other than alcohol use disorder, the literature points to even greater heterogeneity between 
studies – in part owing to methodological difficulties, such as the issue of possible 
misclassification of non-intentional lethal overdose. However, the reported risk of completed 
suicide  (expressed as the standardized mortality ratio) in opioid use, intravenous drug use or 
mixed drug use has repeatedly exceeded that in alcohol use disorder, with standard mortality 
ratios ranging from 5 to 10.48,50,51  
1.5.1.4 Personality 
Personality characteristics have been suggested to act as stable risk factors that either 
predispose to psychiatric disorders or in themselves independently confer an increased risk of 
completed suicide.52 Among overlapping personality characteristics, “impulsive aggression” 
and “hopelessness or pessimism” have been put forward as two major dimensions associated 
with suicidality.52,53 Although impulsivity does not necessarily include aggressive behavior, 
the two predispositions have repeatedly been shown to be correlated54,55 and to confer 
independently increased risks of highly lethal behavior, including violent suicide attempts 
and suicide.52 Moreover, impulsivity is one of the two domains of diagnostic criteria in 
attention-deficit/hyperactivity disorder.39,40 In both an earlier meta-analysis and in a more 
recent Swedish population-based study featuring adjustments for comorbid psychiatric 
disorders, attention-deficit/hyperactivity disorder been reported to be associated with 
increased risks of completed suicide (odds ratio [OR]: 5.91 [95% confidence interval {CI}: 
2.45–14.27], in the Swedish study).56,57  
1.5.1.5 Chronic somatic illness 
A number of somatic illnesses have been shown to be associated with raised suicide risks, the 
most commonly associated conditions being chronic obstructive pulmonary disease, coronary 
heart disease, neurological conditions and several forms of cancer.29,58–61 These risks have in 
matched nested control studies from England and Denmark been shown to be elevated among 
patients in both primary and inpatient care, albeit with higher independence from psychiatric 
factors among hospitalized patients.62,63 Investigation of noncancerous pain-related 
conditions in the National Death Index from the Department of Veterans Affairs Healthcare 
System (n = 4 863 086), revealed, after adjustment for age, sex and somatic and psychiatric 
comorbidity, that back pain, migraine and psychogenic pain conferred increase suicide 
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risks.64 Diabetes mellitus has, in large prospective (n= 1 234 927) and retrospective matched 
(n= 1 512 405) cohorts in, respectively, South Korea65 and Sweden66, been shown to increase 
the risk of completed suicide two- to four-fold (OR in males: 2.55 [95% CI: 1.30–5.00], OR 
in females: 3.64 [95% CI: 1.12–11.86], in the South Korean study; and relative risk for both 
sexes: 3.36 [95% CI: 2.99–3.79], in the Swedish study). In a sample of consecutively 
performed autopsies in the catchment area of Helsinki, Finland, Forsman and colleagues 
showed that suicide victims displayed, on average, elevated HbA1c levels of glycated 
hemoglobin, consistent with diagnostic criteria for diabetes, yet had lower levels of estimated 
premortem blood glucose than non-suicidal controls.67  
1.5.2 Societal-level factors  
1.5.2.1 Access to and lethality of means 
The proportion of medically identified suicidal acts that result in death varies noticeably 
across methods of attempted suicide. Incidence rates during the years 1990 to 2003, reported 
from independent population-based Australian and American studies, ranged from 85% to 
97% for the use of firearms to 1% to 7% for the most commonly used methods, medication 
overdose and laceration with sharp instruments.68–70 Although the degree of lethality is of 
paramount importance for the percentage of fatal outcomes, ease of use and accessibility also 
greatly influence choice of method and the absolute number of deaths.71–74 There are reports 
of reduced suicide rates resulting from restriction of means by way of both population-level 
natural experiments (e.g., transition from toxic to non-toxic household gas and decreased 
toxicity of motor-vehicle exhaust) and state interventions (e.g., restriction on pesticide sales, 
restricted access to firearms and market withdrawals of the opioid analgesic 
dextropropoxyphene). Reported findings have, however, predominantly been of an ecological 
nature and have almost exclusively involved either common or highly lethal methods.75–80 
Yet, it has been argued that, although the reduction of accessibility of a method decreases its 
specific use in suicide, the method is readily replaced by other methods, so-called means 
substitution.81,82 This claim has been partly called into question, however, by studies 
reporting relatively low rates (5%–20%) of fatal re-attempts in short-term and long-term 
follow-up periods, even after highly lethal index events.35,74,83  
1.5.2.2 Access to health care provision 
In Finland, studies of the organization of mental health have shown that the availability of 
outpatient services has protective effects on suicide.84 Other ecological studies have 
investigated whether suicide rates might be affected by specific indicators of health care 
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availability, such as numbers of general practitioners, psychiatrists, physicians, clinical 
psychologists and social workers. Adjusted for socioeconomic variables, findings from 
Austria, Japan, Slovenia and the United States have shown an inverse correlation between 
measures of health care density and suicide rates.85–88 However, in a later ecological study of 
191 countries (which, admittedly, did not adjust for socioeconomic variables or the quality of 
reported suicide data), the authors concluded that countries with superior psychiatric services 
have higher suicide rates.89 With regard to level of care prior to death, Appleby and co-
authors found, in a case-control study from the United Kingdom, that suicide victims had had 
their level of care reduced within the three months prior to death. Reduction of care included 
reduced appointment frequency, lowered medication dosage, and transfers to a less 
supervised location.90 
1.6 THEORETICAL MODELS OF THE SUICIDE PROCESS  
Since the beginning of the 20th century, several theories of the suicide process have been 
developed based on single or combined biological, psychological and social models.91 In 
recent years, models proposed by a number of research groups – including the Stress–
Diathesis Model of Mann and colleagues; the General Model of Suicidal Behavior of Maris 
and colleagues; and The Integrated Motivational–Volitional Model of Suicidal Behavior of 
O’Connor and colleagues – have further distinguished distal, predisposing factors (such as 
genetic predisposition, adverse childhood experiences and personality traits) from proximal, 
trigger or volatile factors (such as acute psychiatric illness, sudden adverse events and the 
availability of lethal methods).92–94 
 
Figure 1.6. Examples of distal and proximal risk factors for suicide. 
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A further elaboration is Dwivedi’s scheme of the Life Span Model of Suicide, which 
integrates biological genetic and epigenetic diathetic and proximal stress factors with Joiner’s 
Interpersonal Theory of Suicide.95 Joiner’s proposal is that a capability of suicide develops 
throughout life (by repetitive exposure to trauma, violence, self-harm or death) but is 
counteracted by the innate fear of death or by an insufficient desire to commit suicide. This 
desire is, according to Joiner, made up of, and dependent upon, degrees of thwarted 
belongingness (social alienation or loneliness) and perceived burdensomeness. Joiner’s 
theory has been evaluated empirically, with results suggesting robust effects of perceived 
burdensomeness on suicide ideation; however, equally firm evidence regarding completed 
suicide is still lacking.96 Dwivedi’s model, which is founded on postmortem brain studies, is 
an attempt to link psychological and neurobiological approaches to suicide research. 
1.7 NEUROBIOLOGICAL FINDINGS 
1.7.1 The serotonergic system 
Historically, evidence of the contribution of low levels of serotonin (5-HT) to suicide risk 
began to emerge in the 1970s, after low levels of the 5-HT metabolite 5-hydroxyindoleacetic 
acid (5-HIAA) were found in the brainstem and cerebrospinal fluid (CSF) of individuals who 
had committed suicide.97,98 Low CSF 5-HIAA levels were later found in depressed subjects 
who had attempted suicide, subjects who had attempted suicide multiple times and subjects 
who had attempted suicide using violent methods.98 Further, findings of low serotonergic 
functioning have also been replicated in studies of high-lethality suicide attempters and 
individuals with elevated lifetime aggression 99–103. Finally, long-term prospective studies 
have also uncovered an increased risk of completed suicide among individuals with lower  
5-HIAA levels in CSF.104  
There has been a major interest in finding regional differences in serotonergic dysfunction in 
the brain, and several replicated studies have suggested reduced expression of the 5-HT 
transporter (SERT) in prefrontal and anterior cingulate cortices – areas involved in decision 
making and regulation of impulsivity.105,106  With regard to genes coding for SERT, 
previously reported positive associations between the less functional short allele of the 
SERT-linked polymorphic region (5-HTTLPR) and both depression and completed suicide 
have, in later meta-analyses, not been corroborated. Nevertheless, 5-HTTLPR is still thought 
to play an important role in violent suicidal behavior.107,108 
Further evidence of low serotonergic function in completed suicide is findings suggesting the 
activation of compensatory mechanisms resulting from low 5-HT and 5-HIAA levels, such as 
 10 
up-regulation of the 5-HT1A and 5-HT2A post-synaptic receptors in the brainstem and frontal 
cortex, respectively.109 The 5-HT2A receptor is also expressed on blood platelets, where it has 
been found to be up-regulated among suicide attempters.110 Age-dependent differences 
between adults and adolescents in expression and functioning of the serotonergic system after 
antidepressant exposure – as reflected by differences in density of 5-HT receptors, as well as 
in the expression of SERT and the function of tryptophan hydroxylase – have been shown in 
animal models.111–113 The serotonergic changes appear to occur in a wide range of conditions 
and have been proposed to characterize violent suicidality per se rather than specific 
psychiatric disorders.114–116 Altogether, there is a considerable amount of evidence for the 
relevance of serotonergic dysfunction as a biochemical trait in depression, aggression, 
impulsivity and violent behavior, including suicide.117 
1.7.2 The noradrenergic system 
Norepinephrine contributes in the modulation of several behaviors, including stress-response 
behavior, decision making and regulation of the sympathetic nervous system. Increased levels 
of norepinephrine are associated with insomnia, anxiety and irritability, while low levels are 
coupled to lethargy and loss of focus.  The relationship between stress, on the one hand, and 
development of depression, suicidal behavior and suicide, on the other hand, has been 
convincingly demonstrated.118  Different forms of distress, including pain, activate the release 
of norepinephrine in locus coeruleus, and prolonged states seem to induce neural changes in 
this area, with an increased number of cells 119. While postmortem studies of suicide victims 
have found indications of cortical noradrenergic overactivity (e.g., fewer noradrenergic 
neurons in locus coeruleus and higher binding to both alpha-1 and alpha-2 adrenergic 
receptors in the prefrontal cortex),120,121 measurements of norepinephrine and its metabolite 
3-methoxy-4-hydroxyphenylglycol in CSF or urine have not conclusively been shown to be 
markers of completed suicide.122–124  
1.7.3 The hypothalamic-pituitary-adrenal-axis response system 
Among the oldest and most reliable findings in biopsychiatry is the altered activity of the 
hypothalamic-pituitary-adrenal axis in depression.125 The main function of the hypothalamic-
pituitary-adrenal axis is regulation of the stress hormone cortisol – a fat-soluble steroid that 
counteracts inflammation and elevates blood glucose. In addition, the hypothalamic-pituitary-
adrenal axis interacts in a complex manner with the noradrenergic, serotonergic and 
dopaminergic systems of the brain. 
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As a stress response, corticotrophin-releasing hormone (CRH) is released from the 
hypothalamus and activates the secretion of adrenocorticotropic hormone from the pituitary 
(ACTH); ACTH acts, in turn, on the adrenal cortex, which produces and releases 
corticosteroids, including cortisol. Increased blood levels of corticosteroids downregulate 
further release of CRH and ACTH from the hypothalamus and pituitary, respectively.126 
Elevated levels of cortisol in blood and CSF have been shown to be strongly associated with 
depression, in particular with treatment-resistant depressive states.127Further, depressed 
individuals have been found, radiologically, to display enlarged pituitary and adrenal 
glands128 and, biochemically, to respond abnormally to ACTH and the dexamethasone-
suppression test. i  
In earlier postmortem studies, albeit in the absence of information regarding psychiatric 
comorbidity, suicide victims have been shown to have enlarged adrenal glands, higher 
concentrations of CRH in CSF and a lower number of corticotropin-releasing-factor binding 
sites in various brain regions, compared to non-suicidal controls.129–131 Although the 
associations to suicide are convincing, it has been proposed that the findings represent 
identification of biological substrates of depression and not of suicide per se. 
1.7.4 Heredity and genome-wide association studies 
Completed suicide is highly heritable and has been shown to be transmitted independently of 
psychiatric disorders. Findings from aggregated patterns of suicide among biological and 
non-biological relatives clearly supports the role of genetic influences; however, intermediate 
behavioral phenotypes, such as impulsive aggression, are likely to moderate these 
influcences.132,133 
Genome-wide association studies have the capability to analyze over a million single-
nucleotide polymorphisms at once, thus offering an efficient way of in an unbiased fashion 
exploring large parts of the genome. Whereas several genome-wide association studies have 
been performed for psychiatric disorders and suicidal behavior, only two peer-reviewed 
published studies have included suicide completers.134,135 Gene-expression analyses have 
identified possible candidate genes linked to function in the prefrontal cortex, to neural-cell 
death and to inflammatory response. The same findings have not been reported from other 
                                                
i The dexamethasone-suppression test assesses the functions of the adrenal glands by suppression of the 
secretion of ACTH, which in healthy subjects subsequently decreases blood cortisol levels. Non-suppression 
upon testing is reflected by normal or elevated levels of cortisol even after administration of dexamethasone. 
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genome-wide association studies of non-fatal suicidality, but partly overlap with biological 
pathways identified in studies that have made use of microarray technology to assess large 
parts of the genome.134 
1.8 ASSESSMENT OF SUICIDE RISK 
1.8.1 Prior contact with health care providers 
Although the majority of completed suicides occur in the absence of prior contact with 
mental health care and without prior warning, in psychological autopsies – which are 
admittedly plagued by recall bias – a sizable proportion (30%–50%) of suicide victims have 
been found to have at some time expressed suicidal communication.136–138 It has further been 
estimated, in both a comprehensive review and in a large longitudinal study from the years 
2000 to 2010, that 45% of suicide victims had interacted with a health care provider at least 
one month prior to death.139,140 It has consequently been of great interest to develop readily 
manageable and accurate tools and routines for suicide-risk assessment even outside the 
mental health sector. 
1.8.2 Theoretical difficulties in suicide-risk assessment 
Since the 1960s, several instruments have been established for the assessment of the risk of 
suicidality, including completed suicide. The instruments have been based upon subjective 
reports with differing degrees of validated diagnostic predictability (sensitivityii and 
specificityiii) with regard to future suicidal events. Items used in the instruments can generally 
be categorized as risk factors that are either statistical and trait-dependent (e.g., demographic 
characteristics, previous suicidality and personality traits) or dynamic and state-dependent 
(e.g., current stressors and the severity and intensity of ideation and planning). The number of 
risk factors per test – extracted, by convention from meta-analyses, in order to avoid type I 
errorsiv – or even combinations of several tests, will, however, not necessarily increase 
predictability, in part owing to possible interactions between different factors, to their 
association with each other and to the extent to which they affect the whole model of 
prediction.141,142 Risk-assessment tools have thus been limited with regard to their ability to 
                                                
ii Sensitivity equals the proportion of positive tests among subjects who are affected. 
iii Specificity equals the proportion of negative tests among subjects who are not affected. 
iv Type I error refers to a false-positive finding. If the probability of obtaining a result that is the same or more 
extreme than the actual observed finding is set to 5% (corresponding to a probability value less than 0.05), 5 
out of 100 tests will be falsely positive. Meta-analyses decrease the probability of type I errors, since chance 
findings are not likely to recur in multiple independent studies. 
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distinguish suicide ideators and attempters from suicide completers – groups that might 
ultimately be found to represent distinct entities.143,144  
In a recent comprehensive systematic review by the Swedish Agency for Health Technology 
Assessment and Assessment of Social Services of the most commonly used suicide-risk-
assessment tools (the Beck Hopelessness Scale, the Scale for Suicide Ideation, the Patient 
Health Questionnaire and the Suicide Intent Scale), no tool proved to display adequate levels 
of stipulated accuracy (80% sensitivity, 50% specificity) to predict future suicide 145. 
However, tools designed to predict rare behaviors, such as suicide, are not only difficult to 
construct, but also inherently problematic to fully evaluate in the context of their major 
purpose – immediate and short-term practical management of suicide risk. Even in high-risk 
populations, rare events require large number of tests in order to be accurately evaluated – a 
predicament that, inevitably, will generate many false-positive predictions, resulting in 
unwarranted interventions to prevent the specific outcome. Further, positive prediction of 
completed suicide will, to a certain degree, be prevented by warranted interventions, thus 
affecting the “true” accuracy of the test.  
Nevertheless, risk-assessment tools are thought to perform no worse than clinical judgment. 
In addition, they provide valuable checklists and awareness that direct clinical focus to 
suicide risk and facilitate documentation.146,147  
1.9 PHARMACOEPIDEMIOLOGY IN SUICIDE RESEARCH 
1.9.1 Methodological challenges in suicide research 
Pharmacoepidemiology is “the study of the use and effects, or side effects, of drugs in a large 
number of people with the purpose of supporting the rational and cost-effective use of drugs 
in the population and thereby improving health outcomes.” 148 One major concern within the 
field is the challenges of estimating the impact psychotropic drugs have upon suicide risk, 
regardless of mechanism. Several classes of prescription drugs have been shown to be 
influence suicidality, including completed suicide.149 Owing to methodological challenges, 
including confounding by indicationv, causality between psychotropic treatment and 
suicidality has been highly difficult to corroborate or refute. For many other pharmacological 
substances, prospective randomized controlled trials (RCTs) often serve as the gold standard 
for evaluating desired treatment outcomes and side effects, since true randomization of a 
                                                
v A confounder by indication is “a variable that is a risk factor for a disease/outcome among non-exposed 
persons and is associated with the exposure of interest in the population from which the cases derive.” 278 
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large number of participants will distribute known or unknown confounding factors evenly 
between exposed and non-exposed participants. Prospective RCTs are, however, not feasible 
to perform for evaluation of completed suicide for ethical, practical and economic reasons. 
Apart from it being ethically indefensible to conduct trials that, by comparing active 
treatment to placebo, could potentially lead to unnatural death in somatically healthy 
individuals, completed suicide is such a rare event that any study would require sizable 
samples and extensive periods of observation to detect differences between treatment arms 
upon statistical analysis. Thus, the research field has been forced to use non-experimental 
observational studies (cohort, case-control, case-crossover, cross-sectional or ecological 
designs) or to pool data from performed RCTs in registered drug trials – methods with 
varying degrees of strengths and limitations.  
1.9.1.1 Propensity-score matching 
The propensity score is the probability of treatment assignment conditional on observed 
baseline characteristics. By matching individuals with identical propensity scores, it is 
possible to mimic a RCT, since a number of baseline covariates will be evenly distributed 
between exposed and unexposed individuals. Further, by reducing the propensity score to a 
single covariate, degrees of freedom and statistical power is spared allowing for smaller study 
samples without loss of precision, thus making feasible matching, stratification or 
adjustments even for rare events and subgroups. In theory, the propensity score would suffice 
as the only variable to match for if the number of constituent covariates were large enough, as 
this would yield a precise estimate even in the presence of non-identical covariates (such as 
sex). However, similar to the process of creating suicide-risk-assessment tools, the selection 
of a set of covariates that accurately estimate the propensity for suicide is challenging. 
Further, the method has also been criticized as possibly increasing imbalance between groups 
by wrongly assuming complete randomization even when such randomization is not feasible 
and should be counteracted by alternative statistical measures, such as randomized 
blocking.150 
In the review of the literature, the drug classes antidepressants and antipsychotics (including 
lithium) have been investigated with respect to existing epidemiological findings in support 
of antisuicidal or prosuicidal effects. 
1.9.2 Antidepressants 
By virtue of their ability to effectively treat the arguably strongest risk factors for  
suicidality – depression and suicidal ideation – it has been hypothesized that different classes 
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of antidepressants might exert protective effects with regard to both completed suicide and 
nonfatal suicidality.151,152 However, from their introduction in the early 1960s, imipramine 
and other tricyclic agents have, in case reports, been linked to onset of aggression and 
suicidal ideation.153 Likewise, the first early reports of suicidal ideation and self-destructive 
behavior associated with selective serotonin re-uptake inhibitors (SSRIs) emerged in the late 
1980s and early 1990s.154–156 Concerns raised over SSRI-induced suicidal behavior and 
completed suicide were later, in the 1990s and early 2000s, contested by results from meta-
analyses of RCTs and propriety clinical data (n ≈ 30 000, 1983–1997) previously submitted 
to the United States Food and Drug Administration (FDA) and the Medicines Evaluation 
Board of the Netherlands.152,157,158 Concurrently, ecological studies were published that 
reported inverse trends of falling suicide rates and increased sales of SSRIs in the Nordic 
countries and the United States.159,160 Subsequent published ecological data from more than 
79 other countries revealed, however, discrepancies in this correlation.88 Nevertheless, most 
subsequent studies from pooled RCTs and meta-analyses have not found evidence of an 
overall greater risk of completed suicide associated with antidepressant treatment.5,161,162 Nor 
have population-based cohorts (n = 219 088; n = 27 712) and propensity-score-adjusted 
cohorts (n = 287 543) in the United Kingdom, Holland and Canada revealed significant 
differences between specific classes of antidepressants in this regard.163–165 Firm evidence of 
antidepressants carrying a distinct protective effect for completed suicide has limited support 
in the literature, but has nonetheless been found for specific medications (sertraline and 
fluoxetine), as well as in nationwide studies that have taken pharmacoadherence into 
account.6,7,166–168 
Standardized suicide rates in clinical trials reported to the FDA since year 2000 have declined 
by 96% and 63% in patients treated with antidepressants and placebo, respectively, while at 
the same time, suicide rates in the US have increased. As patients’ demographic 
characteristics have remained the same, the findings may reflect medications’ antisuicidal 
effects. It is, however, more likely that by way of more efficient screening, suicidal patients 
are to a greater degree, being excluded from clinical trials. 169  
Although the overall support for antidepressants exerting a prosuicidal effect is lacking, 
discrepancies have emerged with regard to risks of adverse events among the youngest and 
oldest age strata (younger than 25 years of age and older than 65 years of age, respectively). 
For instance, in a large (n ≈ 1.2 million) propensity score-matched study of elderly subjects in 
Ontario, Canada, Juurlink and co-workers found that SSRI treatment increased the risk of 
violent completed suicide during the first month of treatment (OR: 4.8, 95% CI: 1.9–12.2).170  
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1.9.2.1 Antidepressants in pediatric populations 
After reports of possible increased risks of suicidality among pediatric patients treated with 
the SSRI paroxetine, the FDA released in 2004 their conclusions from a meta-analysis of 
pooled data (n = 4582) from 24 RCTs of antidepressant use in pediatric patients, as well as a 
black-box warning regarding antidepressant use among young people that would be 
expanded in 2007. In the dataset on which the FDA based its conclusions, treatment with 
SSRIs showed an overall increased risk of suicidality, but not of completed suicide 171. 
However, in a broadly matched case-control study (n = 47), Olfson and co-authors have 
reported an increased risk of completed suicide in a pediatric setting, albeit with a CI whose 
upper limit was infinity.172 As a later natural experiment in a cohort of 2.5 million American 
youths, the issuance of the FDA warning was followed by reduced sales of antidepressants, 
as well as a paradoxical surge in psychotropic drug poisonings, but no change with regard to 
completed suicides.173  
The reported risk of suicidality among children and adolescents has been further investigated 
for other classes of antidepressants. In neither a large retrospective cohort (n = 36 842), nor a 
large propensity-score-matched cohort (n=124 097) nor a meta-analysis of RCTs (n=3335) 
have any clinically meaningful differences between antidepressant medications been 
uncovered with regard to suicidality.174–176 Concerning duration of antidepressant exposure in 
this group, it has repeatedly been shown that the risk of non-fatal suicidal events is increased 
during the first weeks of antidepressant treatment.177,178  
1.9.3 Antipsychotics 
The risk of completed suicide in schizophrenia has been argued to be mainly related to 
psychotic and affective symptoms, foregoing suicide attempts and the number of psychiatric 
admissions, with as many as 2% of patients dying within five years of diagnosis; the lifetime 
suicide risk has been estimated to be as high as 10%.179–181  Aside from schizophrenia 
research indicates that psychotic experiences per se increase the risk of suicide.182 Prefrontal 
dysfunction has been suggested as a common biological trait in schizophrenia and lethal 
suicidality, implying that antipsychotics that improve prefrontal function would also have 
antisuicidal effects.183 The second-generation antipsychotic clozapine is unequivocally the 
medication that mediates the highest prefrontal availability of noradrenaline, dopamine and  
5-HT.184 In both a random-effect meta-analysis (n ≈120 000), a study using a population-
based retrospective cohort (n ≈ 5.2 million), nested case-control studies (n = 26 046) and 
other observational studies, clozapine has shown advantage compared to other psychotropic 
agents with regard to both decreased risk of completed suicide and all-cause mortality in 
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schizophrenia.185–189 Clozapine is, further, one of the few medications that have been 
evaluated in an RCT with suicidality as an outcome; based on its antisuicidal effects, it is to 
date the only drug with an FDA-recognized indication of suicide risk (in schizophrenia).190 
Although, in retrospective review reports and RCTs in bipolar patients, other first-generation 
and second-generation antipsychotics have been reported to be associated with non-lethal 
suicidality and akathisia-related suicidal ideation,191–193 large-population-based studies, as 
well as a recent meta-analysis including RCTs across several diagnostic categories, have not 
shown clear associations to completed suicide.186,187,194 The question of antipsychotics 
potentially protective effects with regard to all-cause mortality and suicide has been measured 
in the treatment of schizophrenia.195–198 In the few studies that have been associated with 
increased risks of completed suicide during treatment with antipsychotics, the use of first-
generation antipsychotics has been predominant, and both inadequate dosage of and non-
adherence to neuroleptic treatment have been common.199,200 
Antipsychotic treatment in schizophrenia has been proposed to follow a U-shaped response 
curve with regard to completed suicide among patients receiving low-dosage and high-dosage 
regimens.196,201–203 With regard to pooled RCT data from the FDA (n = 10 118) or from 
FDA-defined search methodology (n = 5123), no differences have been shown in rates of 
attempted or completed suicide between placebo-treated and drug-treated groups for the 
second-generation antipsychotics olanzapine, risperidone, quetiapine and ziprasidone.204,205 
1.9.4 Lithium 
A large number of studies conducted since the 1970s have confirmed lithium’s antisuicidal 
properties, as well as a protective effect upon all-cause mortality in affective disorders 206. In 
a meta-analysis of RCTs from 2013 (48 trials; n = 6674), lithium was found to be superior to 
placebo, decreasing the number of completed suicides 7.8-fold and death by any cause 2.6-
fold.207 Notwithstanding the large body of evidence concerning lithium’s antisuicidal 
properties, relatively little is known about the substance’s mechanism of action. Mood-
stabilizing, anti-aggressive and anti-impulsive effects have been put forward as likely 
mechanisms, although further research is needed for the identification of causal pathways. At 
any rate, a vital prerequisite for lithium’s antisuicidal function is good adherence.208 In 
clinical practice, on account of substance’s narrow therapeutic window, the concentration of 
the lithium in serum is regularly monitored, allowing detection of suboptimal adherence. 
However, for other psychotropic agents – with the exception of clozapine – similar 
biochemical monitoring is not regularly performed.  
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1.10 ADHERENCE 
Adherence has been defined by WHO as “the extent to which a person’s behavior – taking 
medication, following a diet, and/or executing lifestyle changes – corresponds with agreed 
recommendations from a health care provider” and has been estimated to be as low as 50% 
even in developed countries and in psychiatric disorders. Non-adherence is recognized as a 
significant public health issue as it is related to a number of directly adverse health outcomes, 
increased costs of medical care, worse prognosis and, ultimately, premature death.209 210 For 
major psychiatric conditions, the dynamic relationship between the degree of disease and 
level of adherence is of particular importance, since reasoning skills, insight and motivation 
are all greatly affected by severe mental illness.211 Non-adherence is, however, considered to 
depend on number of variables, which, according to WHO, can be schematized as a five-
dimensional model consisting of social and economic factors, health-care-related factors, 
condition-related factors; therapy-related factors and patient-related factors. The most 
effective approaches to improving adherence have been shown to target several factors using 
multiple interventions.209 
1.10.1 Measuring adherence 
Incorrect measurements of adherence lead to difficulties in interpreting results from clinical 
trials, since they will yield incorrect calculations of treatment efficacy and dose–response 
relationships. By extension, possible real-world effectiveness becomes even more difficult to 
estimate.212 There is, however, no gold standard for measuring medication adherence. 
Although subjective measurements based on patient diaries, interviews and questionnaires are 
the most frequently used methods for evaluating medication use, their accuracy is 
compromised by confirmation bias and recall bias.213,214 Such methods also run the risk of 
changing the use of medication and reporting behavior of the participants, by increasing both 
medication purchases and intake through “white-coat adherence” 215. This phenomenon may 
in itself be an important therapeutic intervention, but it gives rise to an artefactual inflation of 
adherence when it forms the basis for inferences made regarding estimated use of medication 
in the general population.  
Direct objective and biological measures of medication use include sampling of body fluids. 
Such analyses are also capable of confirming therapeutic drug concentrations, in evaluations 
of intended efficacy. Nevertheless, as in the case of interviews, anticipated body-fluid 
sampling is associated with alterations in medication-use behavior. A few studies have 
implemented unannounced blood or urine sampling, in order to investigate unreported co-
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medication and non-adherence to prescribed medications.213,216–219 Yet, these studies have 
been conducted in inpatient- or outpatient-care settings and, in most cases, measured in a 
limited number of selected substances, making them prone to selection bias.   
An indirect objective measure that is both less prone to “white-coat-adherence” and cost-
effective to implement for a large number of participants is the use of database analysis of 
consecutive dispensations of prescriptions. This form of measurement assumes, however, that 
prescription-filling patterns correspond to real-world adherence – that is, that patients 
regularly take medications as they are generally prescribed. Such methodology is therefore 
not suited for off-label use and unconventional dosage. 
1.10.2 Prescription and dispensing patterns in suicide research 
In contrast to distinct periods of exposure described in proprietary data from performed RCTs 
in meta-analyses, the clear majority of pharmacoepidemiological studies investigating the 
association between medication and suicidality have used rather simplistic definitions of 
drug-use periods. Periods of exposure to psychotropic medications have most commonly 
been modeled either on defined daily doses (DDD)vi; on an assumption of one-tablet-per-day 
use; or on fixed time windows, such as any purchase of medication 30, 90 or 180 days prior 
to the suicidal event. Regardless of how methods model continuous exposure – for example, 
by requiring overlapping prescriptions or allowing grace periods between prescriptions – 
individual prescription-filling behaviors are challenging to fully account for, which has 
yielded substantial differences between methods.220 In fields such as cardiology and 
endocrinology, it has been shown that difficulties in defining continuous exposure run the 
risk of producing misleading results with regard to protective and harmful effects.221,222 
While numerous ecological population-based studies have modeled temporal patterns of 
antidepressant prescriptions and concomitant alterations in rates of completed suicide, the 
number of studies that at an individual level have tried to construct predictive models linking 
prescription purchasing patterns to suicidal behavior is limited; what’s more, existing studies 
have focused only on non-lethal events.223 Adherence to antidepressants, measured simply as 
a dispensing pattern of more than one purchased prescription, has in nationwide Danish and 
Finnish cohorts been shown to be associated with decreased probability of completed 
suicide.6,7 Likewise, in a study using similarly modeled adherence to prescriptions from 
                                                
vi “The DDD is the assumed average maintenance dose per day for a medication used for its main indication 
in adults”.148 
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from Quebec, Canada, treatment with antipsychotics was shown to lower the risk of suicide 
in schizophrenia.224 At the same time, such studies have not been able to answer the 
following important questions:  
 Does initiation of treatment transiently increase the risk of suicide?  
 Might periods without prescriptions merely reflect diminished purchasing behavior owing 
to undertreated severe psychiatric disorder?  
 Having filled a prescription, how often do patients actually take their medications?  
Thus, even with more sophisticated models of medication use, prescription purchasing 
patterns still have limitations in their use as a proxy for actual pharmacological treatment and 
for conceivable direct biological effects of relevance for the suicidal process.  
1.10.3 PRE2DUP 
Through the use of registry-based prescription data, Tanskanen and co-workers have applied 
their method, PRE2DUP (an acronym for From Prescription Drug Purchases To Drug Use 
Periods),225 in an effort to more precisely estimate continuous drug exposure.226–228 The 
validity of PRE2DUP has been evaluated in an interview-based study of person-level 
agreement between self-reported use of medication and modeled dispensation.229 In 2006, 
Tiihonen and co-workers incorporated PRE2DUP in one of the few published studies 
employing propensity-score adjustments that have reported a protective effect with regard to 
completed suicide during SSRI treatment.167 
In contrast to methods (fixed time windows, fixed dosage and prescribed dose) that are static 
and thus imprecise in their use of parameters to create medication-use periods, PRE2DUP 
creates data-driven models of personal medication-purchasing behaviors by analyzing the 
individual user’s purchasing history. Exposure time periods are constructed and estimates of 
used doses are calculated based on the purchased amount of DDDs recorded in prescription 
databases. As alterations in purchasing behavior can be caused by changes in prescribed 
dosage, stockpiling, shortage at the pharmacy and other factors affecting the personal pattern 
of medication purchase, PRE2DUP has implemented sliding averagesvii of daily dose. 
Sliding averages smoothen random variation between dispensations regardless of the cause of 
purchasing-behavior alterations and individualize an estimated single continuous drug use 
period.  
                                                
vii Sliding averages of daily dose in PRE2DUP are calculated from three subsequent purchases with weighted 
averages, whereby the last purchase affects the estimate most. 
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Figure 1.10. Flow chart of core processes in PRE2DUP. Modified from Tanskanen et al., BMC Medical 
Informatics and Decision Making (2015). 
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1.11 PHARMACOTOXICOLOGY  
Forensic-toxicological detection of pharmacological substances plays a vital role in modern 
forensic investigation, given the fact that poisoning is one of the leading external causes of 
death worldwide. In the United States, both pharmaceutical medications and illicit drugs 
cause the vast majority of poisoning deaths,230 whose rates, given the infrequency of 
toxicological investigation, have presumably been underestimated.231 Compared to 
psychological autopsies, medical records and analysis of prescription data, toxicological 
findings reflect more accurately the presence of biologically active substances and their 
relevance for the cause of death. 
1.11.1 Methods of toxicological detection  
For the past few decades, efficient techniques for broad systematic chemical analyses have 
been developed and used in a variety of fields. In the forensic sciences, techniques using 
combinations of liquid chromatography (LC), gas chromatography (GC), mass spectrometry 
(MS) and time-of-flight technology (TOF) have predominated for use in screening for 
substances, as well as for use in validation and quantification.232 
Chromatography is a separation technique by which compounds are split into smaller 
constituents in either liquid or gas form. As a compound passes through a chromatography 
column, its constituents will react with the column’s absorbent lining, and resulting variances 
in flow rates and retention times will make it possible to differentiate the constituents. By 
coupling the chromatographer to a spectrometer, the constituents can be further broken down 
into charged ionized fragments. On account of their unique mass-to-charge ratios, the 
constituents can then be identified and their concentrations quantified.  
 
Figure 1.11. LC-MS spectrum. Reprinted from Wikipedia.org.   
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In TOF–MS, charged ions are passed through a vacuum chamber with a certain kinetic 
energy. Ions with a lower mass-to-charge ratio will travel faster through the chamber, and the 
time distribution of detection is used for precise measurements of fragment sizes.  
The combined techniques of LC–TOF–MS have proved to be a fast and sensitive method for 
screening a large numbers of known and unknown substances. However, with regard to 
sensitivity, specificity and dynamic ranges, the method has been surpassed by the much 
slower combined techniques of GC–MS and LC–MS, making those techniques optimally 
suited for validation and quantification.233 
1.11.2 Pharmacotoxicology in forensics 
Numerous published reports have presented pharmacotoxicological data and trends with 
regard to several aspects of completed suicide (e.g., overdose-related findings; differences in 
age, sex and ethnicity; differences in choice of method; concurrent findings of illegal 
substances or alcohol; comparison to homicidal deaths; and comparisons of fatal toxicity 
indices),234–240 with psychotropic agents generally being the most commonly reported 
substances found in deaths adjudged to be the result of suicide. However, routines for 
toxicological testing vary greatly worldwide with regard to case inclusion and selection of 
assayed substances,241 with targeted testing being a highly common forensic practice. Thus, 
collected forensic data have often been prone to various selection biases.  
Another difficulty lies in the interpretation of the toxicological results, as levels measured in 
postmortem samples do not necessarily represent blood concentrations at time of death. 
Postmortem drug redistribution – the movement of substances between tissues and fluids 
after death – depends on a number of factors, such as time between death and autopsy, 
anatomical site, cadaveric changes (blood movement, putrefaction and cell death) and 
substances’ pharmacokinetic properties (acidity, lipophilicity and protein binding).242 The 
vast majority of forensically routinely investigated substances have a high postmortem 
central-to-peripheral drug-concentration ratio – the concentration in the heart and liver 
divided by the concentration in the femoral vein – which has been correlated with higher 
postmortem than antemortem blood concentrations, including in the vast majority of 
instances in which fatal poisoning has been ruled out.243–245 Further, both absolute 
postmortem blood concentrations and central-to-peripheral drug concentration ratios have 
been found to be positively correlated to the length of delay between death and autopsy.246,247  
Practically, in instances of measurements of blood concentrations of substances that border 
on fatal toxicity, the general increase in postmortem concentrations may prove to be an 
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interpretative challenge for the coroner in determining whether death resulted from 
intoxication or another, natural cause. However, with regard to detection of substances with 
lower therapeutic ranges or shorter half-lives, increased postmortem concentrations are 
instead favorable, from a perspective of sensitivity, as they result in low rates of false-
negative findings.  
1.11.3 The pharmaco-toxicologico-epidemiology of suicide 
Among studies based upon systematic forensic-toxicological verification, there is still a 
dearth of analyses that make use of controls.248–253 Further, owing to obvious practical and 
legal limitations with regard to antemortem body-fluid sampling, even comprehensive 
forensic datasets have, by necessity, been cross-sectional and descriptive in nature. 
Consequently, whereas reliable postmortem toxicology is likely the closest possible 
representation of actual treatment and biological responses involved in the suicidal process, 
the stated practical and methodological difficulties have thus far prevented use of 
toxicological findings for causal inference. 
The most common use of combined prescription and forensic-toxicological data has been to 
evaluate causes of death and total number of sales of particular medications regionally, which 
has allowed calculation of trends and fatal toxicity indicesviii at the group level. In 1994, 
Isacsson and co-workers investigated the relationship between diagnoses of depression, 
prescriptions and concomitant toxicological findings with regard to use of antidepressants by 
individual suicide victims.254 This longitudinal approach to forensic toxicology in suicide was 
again applied by Isacsson and co-workers to: data from Jämtland County for the period 1985 
to1995 252; SSRI treatment in the Swedish population (1992 to 2000) 255, and on data 
regarding Swedish youths for the period 2006 to 2010.256 Recently, a similar methodology 
was also used in Northern Ireland by Benson and co-workers.257 However, none of the 
aforesaid studies has included combined individual toxicological findings and prescription 
data from non-suicide controls, thus leaving suggested findings of low psychotropic 
adherence and possible mechanisms in completed suicide open to speculation. 
 
 
                                                
viii “Fatal toxicity index is the absolute number of fatal poisonings caused by a particular medication divided 
by its consumption figure (number of deaths/DDD)”. 279 
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2 AIMS 
The overall aim of the thesis has been to investigate possible associations between adherence 
to treatment with prescribed psychotropic medications and completed suicide in the Swedish 
population. The ultimate goal has been to provide new knowledge to promote a better 
understanding of how pharmacotherapy can be improved in groups at risk for completed 
suicide. 
The specific objectives for the included studies are described below.   
 
2.1 STUDY I: SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS AND THE 
RISK OF VIOLENT SUICIDE 
We investigated whether previous findings of an association between the use of 
antidepressants (selective serotonin re-uptake inhibitors) and method of suicide could be 
replicated after adjustments for the use of other substances. In addition, we attempted to 
identify associations related to length of SSRI treatment, age and sex. 
2.2 STUDY II: COMPARISON OF DISPENSED MEDICATIONS AND 
FORENSIC‐TOXICOLOGICAL FINDINGS 
We investigated real-world pharmacoadherence to treatment with commonly prescribed 
psychotropic medications and other non-addictive medications in the Swedish population. In 
addition, we attempted to clarify why factors such as medications’ biological half-lives and 
dosing regimens influenced adherence. 
2.3 STUDY III: ADHERENCE TO PSYCHOTROPIC MEDICATION IN 
COMPLETED SUICIDE 
We investigated the extent to which personal-level adherence to treatment with psychotropic 
medications influences the risk of completed suicide. In addition, we explored differences in 
patterns of prescription dispensations during the year leading up to death, operationalizing the 
dispensation ratio – the number of initiated prescriptions divided by the number discontinued 
prescriptions – as a potential predictor of completed suicide. 
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3 MATERIAL AND METHODS 
3.1 POPULATIONS 
The papers included in the thesis are all nationwide population-based studies. The study 
populations consist of all forensically investigated deaths in Sweden from 2005 to 2013. 
Table 3.1: Description of study designs, populations and outcome variables in the included studies. 
 
 Study I Study II Study III 
Study 
population 
Suicide victims in 
Sweden 2005–2012 
Swedish population  
2006–2013 
Swedish population  
2006–2013 
Study design Case-control study Methodological study Case-control study 
Participants N = 9 553 N = 18 627 N = 15 173 
Data sources National registries 
ToxBase 
National registries 
ToxBase 
National registries 
ToxBase 
Exposure(s) SSRIs Non-addictive prescription 
medications 
Adherence 
Partial adherence 
Non-adherence 
(to treatment with 
psychotropic medications) 
Outcome(s) Violent completed suicide Agreement between the 
Prescribed Drug Registry and 
ToxBase 
Rate of adherence 
Rate of recreational use 
Completed suicide 
Violent completed suicide 
ICD-10 codes 
(outcome[s]) 
X70–X83 
Y20–Y33 
 X70–X83 
 
Covariates Age 
Sex 
Categories of substances 
Type of SSRI 
 Age 
Sex 
Somatic inpatient care 
Psychiatric inpatient care 
Dispensation ratio 
Statistical 
analysis 
Logistic regression Cohen’s kappa 
Shapiro-Wilk normality test 
Welch’s t test 
Mann-Whitney–Wilcoxon test 
Fisher’s exact test 
Logistic regression 
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3.2 DATA SOURCES 
3.2.1 Swedish national registries 
Since 1947, every Swedish resident has been assigned a 12-digit personal identity number 
that is based on one’s date of birth, which, in research contexts, makes linkage of individual-
level data recorded in national registries practically feasible.258 In the current project, all 
records were anonymized prior to data analysis.  
3.2.1.1 The Swedish Cause of Death Registry 
The Swedish Cause of Death Registry is a virtually complete (99.1%) registry on specific 
causes of death that is coordinated by the National Board of Health and Welfare (NBHW). 
Since 1952, registered information has been obtained from death certificates collected from 
local registries. The Swedish Cause of Death Registry includes data on age, sex, date of death 
and, since 1997, ICD-10 codes regarding underlying and contributing causes of death.259 
3.2.1.2 The Swedish Prescribed Drug Registry 
The Swedish Prescribed Drug Registry, managed by the NBHW since 2005, contains 
personal-level information on all dispensed prescription in Sweden. It also includes data on 
generic names of prescribed medications, date of dispensations, Anatomical Therapeutic 
Chemical Classification System codes, dosages, amounts and DDDs.260 
3.2.1.3 The Swedish National Inpatient Registry 
The Swedish National Inpatient Registry, administrated by the NBHW, possesses virtually 
complete (99%) coverage of inpatient episodes in Swedish hospitals since 1987. The registry 
contains information regarding main and secondary diagnoses, as well as their codes 
according to ICD-9 and ICD-10. A previous validation study by the NBHW has shown that 
between 85% and 95% of all diagnoses in the registry are correct.261 
3.2.1.4 The Total Population Registry 
The government agency Statistics Sweden maintains the Total Population Registry, which 
was established in 1968 and contains virtually all data on births and deaths, including sex, 
parish of birth and birth order.262 
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3.2.2 ToxBase 
All studies have used forensic-toxicological data retrieved by the Swedish National Board of 
Forensic Medicine (NBFM). The NBFM conducts all forensic autopsies requested by the 
police in instances of unnatural or unwitnessed fatalities. Forensic autopsies are virtually 
always augmented by toxicological analyses performed at the NBFM’s department of 
forensic genetics and forensic toxicology on routinely collected femoral blood, urine and 
vitreous humor. Toxicological analysis is capable of detecting most legal (and illegal) 
substances and their metabolites at therapeutic (or recreational) levels, and the results are 
registered in the NBFM database, ToxBase.263 
3.3 STUDY DESIGNS 
3.3.1 Case-control studies 
Studies I and III are observational longitudinal studies based on a case-control design. In a 
case-control study, two groups from the same source population with a difference in outcome 
status are followed retrospectively. Once subjects positive for the outcome of interest – cases 
– have been identified, controls (negative for the same outcome) are selected. The selection 
of controls from the source population should be random but can be coupled with matching 
for variables such as age, sex and geographical region. Collected data of exposure to one or 
several risk factors is then used to calculate associated risk estimates, expressed as ORs, for 
the probability of the investigated outcome. The case-control design is well-suited for rare 
outcomes and thus is usually time- and cost-effective. 264 
Figure 3.3. Study design of a case-control study. 
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3.3.2 Methodological study 
Study II is a methodological study. The focus of a methodological study can be described as 
the process used to develop the validity and reliability of instruments and methods to measure 
constructs used as variables in research. A methodological study can examine a single 
method or compare several methods. The purpose is to evaluate the investigated methods to 
facilitate their further development and systematic application. 
In Study II, the PRE2DUP method was applied to data from the Prescribed Drug Registry 
regarding commonly dispensed non-addictive medications, and results were compared with 
toxicological results from ToxBase. Thus, results based on PRE2DUP and ToxBase were, in 
their capacity of alternative measures of ongoing treatment, evaluated in relation to one 
another. 
3.4 OUTCOMES 
3.4.1 Study I and Study III: Violent completed suicide 
The outcome investigated in Study I was violent suicide, defined as a registered ICD-10 code 
in the Cause of Death Registry corresponding to a violent suicide method with certain or 
intentional (X70–X83) or uncertain or unknown intent (Y20–Y33). A sensitivity analysis was 
also performed with the outcome restricted to certain or intentional suicide.  
In Study III, after exclusion of any suicide registered in the Cause of Death Registry as self-
poisoning of intentional (ICD-10: X60–X69) or undetermined intent (ICD-10: Y10–Y19) for 
the purpose of correctly estimating adherence, remaining cases of suicide had been 
committed using violent methods and coded as certain. 
3.4.2 Study II: Agreement, rate of adherence and recreational use 
The primary outcome in Study II was agreement (as measured by Cohen’s kappa) between, 
on the one hand, predicted ongoing treatment by PRE2DUP, based on data regarding 
dispensed prescriptions retrieved from the Prescribed Drug Registry, and, on the other hand, 
forensic-toxicological findings retrieved from ToxBase. A second outcome in Study II was 
the rate of adherence to treatment with dispensed medications, measured as the predicted 
fraction of dispensed prescriptions matching positive toxicology, while a third outcome was 
the rate of recreational use of the investigated medications, measured as the fraction of 
dispensed prescriptions without matching positive toxicology.  
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3.5 EXPOSURE VARIABLES AND COVARIATES 
3.5.1 Study I 
In Study I, the major investigated exposure was SSRI treatment, defined as forensic-
toxicological detection registered in ToxBase of any active substance or its metabolite 
assigned the Anatomical Therapeutic Chemical Classification System code N06AB 
(fluoxetine, citalopram, escitalopram, paroxetine, sertraline and fluvoxamine). Also 
investigated was the duration of SSRI treatment measured from the date of the first dispensed 
prescription to the date of death.  
All models in Study I were adjusted for the type of SSRI and the number of categories of any 
detectable substance other than SSRIs (including other medications and illegal drugs). 
Stratifications or adjustments were also made for age and sex. 
3.5.2 Study II 
In Study II, the major exposure of interest was all prescription medications routinely 
screened by the NBFM, with the exception of addictive medications (benzodiazepines and 
opioids). Included substances all had to be detectable by accredited analytical methods at a 
level equal to or below the lowest limit of each medication’s recognized therapeutic blood- 
concentration range. 
3.5.3 Study III 
The major exposure of interest in Study III was adherence status with regard to ongoing 
treatment with antidepressant and antipsychotic medications as predicted by PRE2DUP, 
defined as:  
Adherence – congruence between predicted occurrence of continuous drug use at the time of 
death and positive postmortem toxicology for the same medication’s active substance or one 
or its metabolites;  
Non-adherence – predicted occurrence of continuous drug use at the time of death in the 
absence of positive postmortem toxicology for all medications in a particular class;  
Partial adherence – a state of simultaneous congruence and incongruence for two or more 
medications in the same class.  
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Adjustments were made for age, sex, previous inpatient somatic care, previous psychiatric 
inpatient care and the dispensation ratio (the number of initiated prescriptions divided by the 
number discontinued prescriptions).   
3.6 STATISTICAL ANALYSES 
3.6.1 Logistic regression 
In Study I and Study III, logistic regression was used to calculate risk estimates for the 
investigated outcome (violent suicide) depending on the various exposures with adjustments 
for covariates of known and unknown confounders.  
In a logistic-regression model, data are analyzed to determine a dichotomous outcome 
(dependent variable) as a function of one or several independent variables. An independent 
variable, frequently representing an exposure, can either be discrete or continuous. Knowing 
the outcome for each point of an independent variable, one can calculate the intercept (the β0 
estimate, reflecting the reference level) and the variable’s coefficient (βn estimates), in order 
to estimate the odds, or logarithmized probability, that a particular value of the variable will 
result in the outcome.  
       
 
π = probability     
 
By exponentiating the β estimates, ORs and corresponding CIs are derived, which commonly 
are used as an approximation of the relative risk under the rare-disease assumption, that is the 
assumption of a prevalence of the outcome of less than 10%. 
 
 
                Table 3.2. Example of output of a logistic regression model 
 
 
 
 
 
 
Term β estimate OR 95% CI P value 
Intercept (β0) −1.92 - - <0.001 
Treatment (β1) −0.09 0.92 0.85–1.23 0.405 
Age (β2) 0.18 1.19 0.92–1.31 0.267 
Sex (β3) 0.36 1.43 1.19–1.65 <0.001 
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3.6.2 Cohen’s kappa 
In Study II, Cohen’s kappa was used to measure agreement between toxicological findings 
and adherence to the corresponding dispensed medications at the time of death as predicted 
by the PRE2DUP method. 
For categorical data, Cohen’s kappa is considered to be a more robust method than agreement 
calculations based on simple percentages, as it takes into account agreement between raters 
that could have occurred by chance. According to the formula below, the coefficient κ can be 
calculated to assume values between 0 (no agreement at all) and 1 (total agreement). 
 
 
 
p0 = relative observed agreement  
pe = hypothetical probability of agreement 
 
 
Figure 3.6. Agreement 
between raters A and B. 
Although no standard levels of agreement have been defined, the following arbitrary 
interpretation of κ has often been used in the literature: poor (κ less than 0.20), fair (κ 
between 0.20 and 0.40), moderate (κ between 0.41 and 0.60), good (κ between 0.61 and 
0.80), and very good (κ between 0.81 and 1.00). 
3.6.3 Tests for equality of means and medians 
In Study II, analyses were carried out to using the Shapiro-Wilk test, Welch’s t test, the 
Mann-Whitney‒Wilcoxon’s and Fisher’s exact test, in order to investigate differences 
between true-positive and false-positive users of metoprolol and quetiapine with regard to 
age, sex, positivity for alcohol, death during any Swedish weekend or holiday, main causes of 
death, comorbid conditions and type of last medication before death.  
Shapiro-Wilk test 
The Shapiro-Wilk test is used to the test the normality of the distribution of data. In cases in 
which data are not normally distributed, the null hypothesis is rejected.  
Welch’s t test 
Welch’s t test, or the unequal variance t test, is a parametric test that tests the hypothesis that 
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two populations have unequal means. Whereas the commonly used Student’s t test assumes 
that tested samples are distributed normally with equal variance, Welch’s t test is used in 
cases of unequal variance, but with a maintained assumption of normal distribution. 
Mann-Whitney–Wilcoxon test 
The Mann-Whitney–Wilcoxon test is a non-parametric test that is used when data are not 
distributed normally; thus, it is commonly regarded as a test of population medians.  
Fisher’s exact test 
Whereas both Welch’s t test and the Mann-Whitney–Wilcoxon test are used to test for 
differences between groups in the case of continuous data, the non-parametric Fisher’s exact 
test is used for categorical data, especially if there is a small sample size.  
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4 RESULTS 
4.1 STUDY I 
4.1.1 Descriptive statistics 
From a total of 10 002 forensically investigated incidents of completed suicide, the study 
population consisted of 9553 subjects. Among men, violent suicide methods were more 
common than non-violent methods (n = 4585 [67.4%] versus n = 2217 [32.6%]), whereas 
among women the relationship was the opposite (n = 1251 [45.5%] versus n = 1500 
[54.5%]). Mean and median ages were similar after categorization according to exposure to 
SSRI treatment and suicide method, ranging from 49.4 years of age to 55.7 years of age and 
from 50 years of age to 57 years of age, respectively. Violent suicide methods were most 
common in all age groups, but most particularly common in the highest age stratum. The 
mean number of categories of substances other than SSRIs was higher in subjects who had 
committed suicide using a non-violent method than in subjects who had used a violent 
method. 
4.1.2 Evaluated risk factors 
The crude risk of violent suicide among SSRI-treated individuals was 0.62 (95% CI: 0.56–
0.69). In a first model adjusting only for age, all estimates, for both men and women, showed 
a protective effect of SSRI treatment on the risk of violent suicide. Yet, after further 
adjustment for sex and categories of other substances, SSRI exposure exerted neither a 
protective nor a predisposing effect on the risk of violent suicide. In a model stratified by sex 
and categorized by duration of SSRI treatment an increased risk of committing violent 
suicide was found for the shortest duration of SSRI treatment (0 to 28 days; OR: 3.6 [95% 
CI: 1.9–6.8]), among both males (OR: 3.6 [95% CI: 1.6–8.1]) and females (OR: 3.9 [95% CI: 
1.3–11.9]). The risk was most prominent among subjects above 50 years of age and was, in 
all groups, attenuated by the length of use. A sensitivity analysis restricted to incidents of 
certain suicide yielded similar risk estimates. 
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4.2 STUDY II 
4.2.1 Descriptive statistics and screening tests 
In the 18 627 included subjects of the study, 63% were younger than 65 years of age, and the 
mean age was approximately 58 years. Females represented approximately 24% of the 
sample. The most common main cause of death, at 41%, was disease related to the 
circulatory system. External causes of morbidity, including vehicle accidents, exposure to 
electric current or exposure to forces of nature, represented the second most common main 
cause of death (33%), after exclusion of incidents of certain or uncertain suicide.  
Overall, PRE2DUP-modeled drug-use matched toxicology in 46% of instances of presumed 
prescribed pharmacotherapy. At the group level, this positive predictive value, or predicted 
adherence rate, was highest for antidepressants, at 71%, and lowest for cardiovascular 
medications, at 22%. Clozapine was the only analyzed medication that had a predicted 
adherence rate of 100%. 
Calculated predicted recreational use, which was generally low, ranged from 0.0% to 1.4% 
(0.3% overall). The highest levels of recreational use were observed for the sedatives 
alimemazine (1.4%) and propiomazine (1.1%), both of which are commonly prescribed to be 
taken as needed. 
4.2.2 Inter-rater agreement and detection versus biological half-life 
Agreement between toxicology and registry data, measured by Cohen’s kappa, was, overall, 
“moderate” (0.56 [95% CI: 0.55–0.57]). The highest level of agreement was observed for 
antidepressants (0.74 [95% CI: 0.73–0.76; range: 0.59–0.82], corresponding to “good” 
agreement), while the lowest level of agreement was observed for cardiovascular medications 
(0.33 [95% CI: 0.31–0.36; range: 0.29–0.65], corresponding to “fair” agreement). 
Antiepileptic and antipsychotic medications displayed, at the group level, “good” agreement, 
at 0.63 (95% CI: 0.61–0.66) and 0.69 (95% CI: 0.65–0.72), respectively (overall range for 
both groups: 0.47–0.98). “Moderate” agreement (0.53 [95% CI: 0.52–0.55], range 0.39–0.59) 
was seen for as-needed sedatives. 
A positively linear correlation between the detection rate and the biological half-life for each 
substance indicated greater probability of detection with longer half‐lives for most 
substances. An exception to this trend, however, was found for cardiovascular medications, 
which displayed an inverse correlation. 
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Figure 4.1 Plot of half-life versus detection rate. The detection rate is plotted against the biological half-life of 
each substance. The relationship is positively linear for all medications, excluding cardiovascular medications, 
for which it is negatively linear. Modified from Forsman et al., Pharmacoepidemiology and Drug Safety 2018; 
27:1112-1122. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In post-hoc comparisons of true-positive and false-positive users of metoprolol and 
quetiapine, a few of the following differences deemed statistically significant were 
uncovered.  
Table 4.1. Comparison of true-positive and false-positive instances of pharmacotherapy for metoprolol and 
quetiapine. 
 Metoprolol 
True positives 
Metoprolol  
False positives 
 
P value 
Quetiapine True 
positives 
Quetiapine  
False positives 
 
P value 
>65 years 64.8% 53.2% <0.0001 7.4% 16.2% 0.1729 
Female sex 27.6% 21.0% 0.0075 29.6% 25.0% 0.6821 
Heart failure 21.1% 15.7% 0.0150 3.7% 0.0% NA 
Ischemic heart disease 30.9% 23.9% 0.0069 3.7% 0.0% NA 
Hypertension 50.1% 35.2% <0.0001 7.4% 17.6% 0.1123 
Lower strength  43.6% 56.3% >0.0001 33.3% 72.1% <0.0001 
Lower dosing 75.0% 89.2% <0.0001 31.6% 65.9% 0.0019 
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4.3 STUDY III:  
4.3.1 Descriptive statistics 
After exclusions and 1:2 matching for age, sex and year of death, the study population 
consisted of 5294 completed-suicide cases and 9879 non-suicide controls. Among cases 80% 
were male and 73% under the age of 65 years (mean age: 52 years [SD: 19.9 years]), whereas 
among controls 82% were male and 72% under the age of 65 years (mean age: 53 years [SD: 
19.1]). The most common causes of death among controls were death attributable to external 
causes and death attributable to diseases of the circulatory system, at 39% and 37%, 
respectively. Rates of toxicological positivity for ethanol and hypnotics were similar in cases 
and controls. Opioids and other addictive substances were more common in controls. With 
regard to previous inpatient care, depression (5.7%), alcohol-related disorders (5.7%) and 
psychosis (2.6%) were most common among completed-suicide cases, and alcohol-related 
disorders (23.8%), drug-related disorders (7.6%) and diabetes mellitus most common among 
non-suicide controls. In comparison with the general population, both cases and controls 
showed higher prevalence for all diagnoses except pulmonary and cardiovascular conditions.  
4.3.2 Differences in prescription dispensations 
Among suicide cases, the number of changes per person increased over the year preceding 
death (all medications, from 0.56 to 1.10; psychotropic medications, from 0.18 to 0.48; and 
verifiable psychotropic medications, from 0.05 to 0.15), while non-suicide controls showed 
similar trends (all medications, from 1.03 to 1.49; psychotropic medications, from 0.27 to 
0.39; and verifiable psychotropic medications, from 0.05 to 0.08).   
With regard to the dispensation ratio, in completed-suicide cases, it decreased, in the year 
preceding death, for all medications (from 1.15 to 0.96), yet increased for psychotropic 
medications and verifiable psychotropic medications (from 1.17 to 1.42, and from 1.30 to 
1.76, respectively); whereas ratios in non-suicide controls decreased for all types of 
prescriptions (all medications from 1.15 to 0.66; psychotropic medications from 1.11 to 0.67; 
and verifiable psychotropic medications from 1.29 to 0.59).  A model for linear fitting six 
months prior to death showed statistically significant slopes of comparable magnitudes for 
changes in dispensation ratios, but in opposite directions (an increasing trend and a positive 
slope for completed-suicide cases, and a decreasing trend and a negative slope for non-
suicide controls) for all psychotropic medications and toxicologically verifiable psychotropic 
medications. 
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4.3.3 Evaluated risk factors 
In a model comparing different degrees of adherence to antipsychotic and antidepressant 
medications as risk factors for completed suicide, complete adherence was set as reference. 
Unadjusted risk estimates for non-adherence and partial adherence to antipsychotics were OR: 
9.51 (95% CI: 2.70–60.30) and OR: 4.59, (95% CI: 1.30–29.16), respectively. After 
adjustments for previous psychiatric and somatic inpatient care, non-adherence and partial 
adherence conferred, respectively, the highest and next highest risk estimates (OR: 9.92 [95 % 
CI: 2.80–63.14] and OR: 4.72 [95% CI: 1.33–30.10]). After a final adjustment for dispensation 
ratio, risk estimates increased further for both non-adherence (OR: 12.43 [95% CI: 2.06–
238.66]) and partial adherence (OR: 6.66 [95% CI: 1.20–128.04]). 
 
Table 4.2. Risk estimates (ORs with 95% CIs) for completed suicide conferred by biochemically verified 
partial adherence and non-adherence to antipsychotic and antidepressant medications. 
  
Completed suicides: 
non-suicide deaths 
OR (95% CI) OR (95% CI) † OR (95% CI) ‡ 
Antipsychotics 
 
 
 
 
Antidepressants 
 
 
Adherence 
Partial adherence 
Non-adherence 
 
Adherence 
Partial adherence 
Non-adherence 
2:18 
128:251 
207:196 
 
39:55 
1186:1064 
415:363 
1 (reference) 
4.59 (1.30–29.16) 
9.51 (2.70–60.30) 
 
1 (reference) 
1.57 (1.04–2.40) 
1.61 (1.05–2.50)  
1 (reference) 
4.72 (1.33–30.10) 
9.92 (2.80–63.14) 
 
1 (reference) 
1.43 (0.94–2.20) 
1.59 (1.03–2.49)  
1 (reference) 
6.66 (1.10–128.04) 
12.43 (2.06–238.66) 
 
1 (reference) 
1.58 (0.71–3.53) 
1.52 (0.67–3.44)  
† adjusted for age, sex, previous psychiatric inpatient care, and previous somatic inpatient care  
‡ adjusted for 1 and dispensation ratio during the four months preceding death 
 
 
For the same model, but comparing degrees of adherence to antidepressants, ORs for 
unadjusted risk estimates for non-adherence and partial adherence were 1.61 (95% CI: 1.05–
2.50) and 1.57, (95% CI: 1.04–2.40), respectively. Adjustments for precious psychiatric and 
somatic inpatient care yielded attenuated risk estimates for suicide, with the risk for non-
adherent users being statistically significant (partial adherence: OR: 1.43, 95% CI: 0.94–2.20; 
non-adherence: OR: 1.59, 95% CI: 1.03–2.49). After a last adjustment for dispensation ratio, 
the latter risk estimate was no longer significant (OR: 1.52, 95% CI: 0.67–3.44). Analyses of 
possible interaction effects between sex and adherence status revealed no significant effects 
for any combination. 
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5 DISCUSSION 
5.1 STUDY I 
In the first study of the thesis, we applied a case-control design to a new theoretical 
framework of suicide-propensity matching at the group level in order to investigate the 
previously studied topic of an association between SSRI treatment and violent completed 
suicide.265 Study I included personal-level information, including prescription history and 
postmortem toxicology, for virtually all forensically investigated incidents of completed 
suicide in Sweden between the years 2005 and 2012.  
By employing a completely new theoretical frame work of comparing only incidents of 
completed suicide, a hypothetical penultimate propensity for this outcome was matched 
between groups. In theory, this approach removes the need of propensity scoring, allowing 
more isolated focus on the phenotype of completed suicide. However, it is still possible that 
earlier exposure to SSRIs could either act as a risk factor or a protective factor, thus affecting 
the pre-existing propensity for completed suicide.  
Figure 5.1.2. Possible penultimate and ultimate outcomes 
 
After adjustments for other substances (including other medications and illegal drugs), our 
results could not replicate earlier findings of SSRIs carrying a protective effect for violent 
suicide.265 On the contrary, our findings indicate that shorter duration of treatment with 
SSRIs, especially among those subjects aged 50 years and older, is an important risk factor 
for the choice of a violent suicide method. The odds ratio for the risk estimate was 3.6 during 
the first month of treatment, yet became attenuated with longer treatment durations in both 
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men and women. Our results are in line with previous findings by Juurlink and co-workers 
regarding the use of SSRIs and completed suicide by violent methods among elderly in 
Ontario, Canada, yet contradict the results of Fazel and co-workers, which were based on 
earlier Swedish data.170,265 Although adjustments for other substances did not render a result 
attaining statistical significance for any of the investigated groups of SSRIs, a robust trend of 
increased point estimates was seen in all models post adjustments. The crude risk of violent 
suicide among SSRI-treated individuals of 0.62 (95% CI: 0.56–0.69) indicated a protective 
effect of treatment on the risk of violent suicide in the absence of an adjustment for other 
substances. To our knowledge, this finding is novel and can explain why previous studies 
have yielded inconsistent results. 
Even if the influence of other substances logically can be explained as a confounding 
variable, because SSRIs are commonly taken together with other substances (as part of 
psychiatric or somatic polypharmacy or substance abuse), the precise mechanisms underlying 
early treatment with SSRIs and the outcome of a violent rather than non-violent suicide 
method is not clear. One possibility is that SSRIs are more readily prescribed to individuals 
carrying specific risk factors for violent suicide, such as life-time aggression, specific violent 
behavior, repeated suicide attempts or poorer impulse control, as has been shown in both 
Finland and Sweden.38,266,267  
Figure 5.1.1. Other substances acting a as a negative confounder prior to adjustments. 
 
 
 
 
 
 
With regard to the timing of the fatal event post dispensation, response to SSRIs in major 
depression has been shown to depend on several factors, including age and 5-HTTLPR 
genotype. Both SSRI users carrying the low-functioning 5-HTTLPR genotype and elderly 
subjects have exhibited latencies to efficiency of therapeutic effect of SSRIs and increased 
risks of violent suicidality and violent suicide.108,268,269 Also of interest are polymorphisms 
within the ABCB1 gene, which have been linked to violent suicidality and male violent 
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completed suicide.270,271 ABC1B encodes P-glycoprotein, which is involved in the transport of 
psychotropic medications over the blood-brain barrier and has been hypothesized to affect 
treatment response. Altogether, these are important genetic findings that further might offer 
explanations of our results. A remaining possibility is that violent suicidal behavior is 
characterized by the continuous need of pharmacological treatment, rather than being caused 
by it.  
5.2 STUDY II 
In Study II, we investigated, in a population-based record-linked methodological study, the 
agreement between continuous drug use as estimated by the PRE2DUP algorithm and 
findings from forensic toxicology. The study group consisted of forensically investigated 
incidents of death in Sweden between the years 2006 and 2013, excluding identified cases of 
completed suicide, as well as cases involving ambulance or hospital care. A similar degree of 
personal-level information from Swedish registries as was used in Study I was applied in 
Study II, with, however, the addition of data regarding previous inpatient care. 
Agreement between PRE2DUP-modeled medication use and forensic toxicology varied 
between the investigated medications, ranging from moderate to good. The highest overall 
level of agreement and predicted adherence was seen for the use of antidepressants, with the 
second and third highest agreement levels being seen for the use of antipsychotic and 
antiepileptic medications, respectively. The lowest level of agreement and predicted 
adherence was found for cardiovascular medications. The level of recreational use was, 
overall, very low, but most common among sedatives commonly prescribed to be taken as 
needed. For all drug classes, with the exception of cardiovascular medications, there was 
higher probability of toxicological detection for medications with longer half‐lives. 
Differences of agreement between prescriptions and toxicology uncovered in subsets of 
quetiapine and metoprolol users confirmed several factors affecting the forensic-toxicological 
detectability, including low-dosage regimens, lower medication strengths and presumed off-
label use. However, regardless of the probable causes underlying lower-than-expected 
toxicological detection of dispensed medications, our findings still reflect confirmed rates of 
ongoing treatment with psychotropic medications at therapeutic levels in the Swedish 
population. 
Our results of estimated adherence to ongoing treatment are of a similar, yet lower, 
magnitude than results reported from biochemical monitoring of pharmacoadherence by 
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means of unannounced sampling: for cardiovascular medications, de Jager and co-workers 
reported an adherence rate of 32%, compared to 22% in our study; and for antidepressants, 
Roberson and co-workers reported an adherence rate of 83%, compared to 71% in our study. 
216,219. In comparison to average rates of adherence reported in a review of older studies from 
1975 to 1996,272 as well as rates reported in a large (n = 36 984) interview-based health 
survey from Canada of psychotropic use in the general population,273 rates of non-adherence 
appear to reflect relatively high reciprocal rates of continuous use of psychotropic 
medications in Sweden, especially considering the fact that our study group had been 
recruited from a forensic setting. In the cited studies, non-adherence to antidepressants was, 
respectively, 46% and 35%, compared to 29% in our study; non-adherence to antipsychotics 
was, respectively, 35% and 42%, compared to 42% in our study; and non-adherence to mood 
stabilizers was 45%, compared to 40% in our study. In a recent study from Austria, only 
about 25% of the acutely admitted psychiatric inpatients had plasma levels of psychotropic 
medications within the expected therapeutic range based on dosage.274  
To the best of our knowledge, no other study has investigated possible recreational use of 
non-addictive prescription drugs. 
5.3 STUDY III 
In Study III, we conducted a matched case-control study investigating different degrees of 
biochemically verified adherence to antipsychotic and antidepressant medications as 
explanatory variables with regard to suicide risk, while using non-suicidal deaths as controls. 
Further, by calculating and comparing the ratio of initiated to discontinued prescriptions for 
psychotropic medications in cases and controls, we operationalized the ratio as a proxy for 
continued need of treatment. As in Study I and Study II, we used toxicological results from 
forensically investigated deaths in Sweden between the years 2006 and 2013, as well as 
personal-level information obtained from national registries regarding primary and 
contributing causes of death, prescription history and previous diagnoses from inpatient care. 
Our results show that, in comparison with adherent use, both partial adherence and non-
adherence to treatment with antidepressant and antipsychotic medications confer increased 
risks of completed suicide. After adjustment for previous somatic and psychiatric care and 
continued need of treatment, risk estimates for use of antidepressants were no longer 
statistically significant, whereas odds ratios for point estimates for use of antipsychotics 
increased (from 4.72 to 6.66 for partial adherence, and from 9.92 to 12.43 for non-
adherence). These findings suggest that a higher continued need of treatment was associated 
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with a greater level of adherence, possibly due to uninterrupted treatment with long-acting 
injectables among more severely ill patients.  
Figure 5.3. Possibilities of an increased association between non-adherence to psychotropic medications and 
completed suicide after adjustment for dispensation ratio as proxy for continued need of treatment, or severity 
of suicidality.  
 
 
 
 
 
 
In fact, in a post-hoc analysis, it was found that 60% (12/20) of fully adherent individuals had 
been prescribed long-acting injectables. Corresponding frequencies of prescriptions for long-
acting injectables for partially adherent and non-adherent individuals were 12% (46/379) and 
11% (45/403), respectively.  
The most obvious explanation for the finding that non-adherence and partial adherence 
conferred increased risks of completed suicide in comparison to complete adherence is that, 
upon discontinued use, pharmacodynamic antidepressive or antipsychotic effects are no 
longer present – particularly given the fact that depression and psychosis are robust risk 
factors for completed suicide. Another possibility is that switching or discontinuation of 
psychotropic medication may give rise to withdrawal or rebound symptoms, causing distress 
or even recurrence of previous suicidality.  
We have argued that a dispensation ratio exceeding 1.0 indicates the continued need of 
treatment, as the ratio only increases by way of dispensations of newly initiated prescriptions 
or renewal of non-overlapping historical dispensations – phenomena that occur in instances 
of insufficient treatment response and increased severity of symptoms and signs, including 
suicidality. Switching of psychotropic medications, however, will not increase the 
dispensation ratio, but will instead “dilute” it toward 1.0. Thus, such dilution may lead to 
underestimation of illness severity, as even switches of medications often represent continued 
need of treatment. In fact, earlier findings by Hedna and co-workers suggest that switching of 
antidepressants confers a more than two-fold increased risk of suicide in the elderly. 275 
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We have shown that the dispensation ratio may be a useful, fairly proximal and easily 
measured objective risk factor for suicide, albeit with overall low expected specificity and 
sensitivity, given the fact that the majority, 55%, of suicide victims lack a psychiatric 
diagnosis, and that only about the same proportion, 53% in our dataset (data not published), 
made any purchase of prescription medication during the four months prior to death.140 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 SOURCES OF ERROR 
Each scientific study is prone to random and systematic error, which, in turn, affects its 
reliability. Random error represents statistical fluctuations in measurement owing to 
limitations in the precision of the means of measure. The size of the random error diminishes 
with the number of observations on account of the self-cancelling of errors above and below 
the true value. Random error is most commonly expressed as the standard error or CI. For all 
studies in the current project, the significance level was set at 0.05. Thus, if the studies were 
repeated, the true value would be expected to occur in 95% of all repeated tests. 
Systematic error, or bias, refers to a deviation from reality, in the course of data collection, 
data analysis, interpretation or publication, that consistently alters the results.264  
Bias is generally subdivided into the following categories: 
Selection bias 
Selection bias stems from the procedure of selecting subjects for a study, in which full 
participation, including follow-up, is influenced as a result of systematic differences either 
between participants and non-participants of the study (affecting the generalizability), or 
between exposed and non-exposed subjects in the study (affecting the comparability). 
Information bias 
Information or misclassification bias results from faults in the way data regarding 
independent and dependent variables, as well as covariates involved in adjustments, are 
acquired and classified at registration. Such misclassification leads to incorrect estimates of 
the association between exposure and outcome. Information bias can be subdivided into non-
differential or random misclassification, which arises when missclassification occurs equally 
in the study groups, irrespective of investigated exposure and outcome; and non-random 
misclassification, which occurs when misclassification is dependent on exposure or outcome. 
Confounding 
A confounder is a third variable that offers an alternative explanation for an association 
between an exposure and an outcome. By not adjusting for the confounder, one distorts the 
actual strength of the observed association between exposure and outcome. In order for a 
third variable to be a confounder, it should be independently associated with the outcome 
and, at the same time, associated with the exposure; in addition, it cannot lie in a casual 
pathway between the exposure and outcome.  
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Figure 6.1. Confounding. 
 
 
 
 
 
Residual confounding refers to unaccounted-for effects of an association, even after measures 
such as matching, stratification and adjustment have been taken into account. Confounding by 
indication is a particularly troublesome example of confounding in observational studies in 
which the risk of the outcome of interest resides in the exposed group prior to exposure, thus 
distorting the actual association to the outcome.  
6.2 STRENGTHS AND LIMITATIONS  
The major strengths of all three of the presented studies reside in the use of large 
comprehensive datasets derived from Swedish national registries and forensic-toxicological 
results regarding medications and other substances.  The national registries possess virtually 
full coverage and toxicology has been consistently performed in suspected cases of unnatural 
death, including virtually all reported cases of completed suicide between the years 2005 and 
2013. This approach has strongly limited the risk of selection bias with regard to the 
investigated exposures. There still exists, however, an inherent selection bias with regard to 
the use of controls – non-suicide deaths – since forensic toxicology is only performed in 
instances in which death resulting from the commission of a crime cannot otherwise be ruled 
out. Nevertheless, although this state of affairs limits the generalizability of the results of 
Study II and Study III, the results can still be to be regarded as conservative 
underestimations: the population of subjects dying by means other than suicide who have 
undergone forensic autopsy has, in comparison to the general Swedish population, shown a 
greater burden of somatic and psychiatric illness, included substance misuse – risk factors for 
both non-adherence and completed suicide.  
Another important source of selection bias in Study III stems from the exclusion of instances 
of death by intoxication, which was necessary in order to make possible investigation of 
adherence status. By way of this exclusion, a third of all incidents of completed suicide were 
unaccounted for, and, in the resulting sample, younger individuals and women turned out to 
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be underrepresented. On the other hand, with regard to both the intentionality of death (on 
account of suicide or accident) and detection of the apparent cause of death, the risk of 
misclassification and selection bias is, by way of the exclusion, expected to be substantially 
reduced. It has been estimated that around half of all unnatural deaths in Sweden are not 
investigated by means of forensic autopsy. In a study sample from 2008, in 63% of such 
cases, no cause of death had been registered on the death certificate; in 29% of cases, death 
was determined to have resulted from an accident, while in the remaining 8% of cases, the 
cause of death was adjudged to be either self-inflicted or unclear.276 Previous research has 
shown that deaths by intoxication are up to 40 times less likely to be categorized as 
completed suicide, rather than death of undetermined cause, than violent deaths. 
Understandably, in the absence of a suicide note, the likelihood that deaths by intoxication 
will be categorized as being of undetermined cause is further increased – indeed, by a factor 
of 45, as compared to a factor of 8 for violent deaths.277  
As toxicological findings of pharmacological substances is the closest possible proxy for 
ongoing pharmacotherapy and biological impact, the possibility of misclassification bias of 
actual influence of substances has, in this project, been minimized. However, a limitation 
exists with regard to information pertaining to the exact time of death, the time of the last 
administrated dose and the possibility of off-label use. Further, medications prescribed at 
lower dosages and substances with shorter half-lives run the risk of not being detected at 
conventional therapeutic concentrations, leading to underestimation of medication intake. In 
fact, a positive correlation between biological half-life and detection rate was shown in Study 
II. In the Study III, substances with half-lives shorter than five hours were excluded, in order 
to decrease the risk of underestimating adherence to the corresponding medications. Thus, the 
exclusion is presumed to have, at the same time, increased the sensitivity of positive 
toxicology.  
Any study without sizeable enough randomization and sufficiently low loss to follow-up will 
run the risk of residual confounding. In Study I, by the lack of outpatient clinical data related 
to the risk of violent completed suicide, the propensity for the outcome was not possible to 
adjust for, resulting in possible residual confounding by indication. Similarly, in Study III, 
although compared calculated risk estimates were based on dispensations, thus presupposing 
psychiatric indications for treatment, indicated medical uses for the investigated psychotropic 
medications are broad. While severity of illness was, in part, accounted for by adjustment for 
the dispensation ratio, residual confounding by indication – specifically, the effect of illness 
severity on both adherence and suicide risk – still cannot be ruled out. 
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Through the use of data from a large number of suicides and non-suicide deaths, good 
statistical power was achieved – a fact reflected by the narrow calculated 95% CIs in all 
studies. An exception, however, are the analyses of adherence status with regard to 
antipsychotics in Study III, owing to the low number of wholly adherent users in our dataset. 
There, the 95% CIs widen with each new addition of covariates to the logistic-regression 
model. The final results, however, are still statistically significant, and the trend across 
analyses is robust. Nonetheless, a possible improvement could be to use propensity-score 
matching. Although consensus is lacking with regard to how propensity scoring should be 
defined and quantified, the method still offers an efficient option for handling a large number 
of covariates that conserves degrees of freedom and statistical power. Using this method, 
smaller sample sizes can be used without loss of precision, making feasible matching, 
stratification and adjustments feasible, even for subgroups and in the case of rare events. 
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7 ETHICAL CONSIDERATIONS 
Suicide has historically been, and at present remains, a taboo subject that often causes 
discomfort, fear and sadness. Consequently, it is of great importance that consideration is 
given to relatives, and to the memory and reputation of the deceased. In order to strike an 
optimal balance between ethical considerations and societal benefits within the framework of 
this doctoral project, we have followed established laws and ethical research principles, as 
well as our personal convictions. 
The current project makes use of information pertaining to deceased subjects retrieved from 
existing forensic databases and national registries, making unnecessary considerations that 
are otherwise relevant in the case of living individuals, such as the risk of physical injury and 
informed consent. In fact, from the viewpoint of the Regional Ethics Board in Stockholm, 
which approved the current project (registration number 2013/1411-31/5), our registry-based 
research data on deceased subjects are not covered by the Swedish Ethical Review Act. 
The raw data obtained from the NBHW was doubly anonymized – through the removal of 
personal identity numbers prior to analysis and presentation of results at the group level after 
analysis – making identification of particular individuals impossible. Sensitive information, 
such as code keys, have been handled conscientiously and stored in a safe place. Through 
these procedures, it has been ensured that no single individual or relative would be harmed by 
the exposure of private information.  
Attempts to contact relatives of the deceased for their consent to enquire about the attitudes of 
the deceased have, for practical and ethical reasons, not been carried out. First, it would have 
been practically difficult to identify relatives to the more than 40 000 subjects included in the 
databases and registries; and, second, contacting relatives seemed ethically questionable, 
since it would run the risk of evoking unpleasant memories. Although use of a smaller sample 
might theoretically have made feasible contact with relatives, it would have violated another 
important ethical research principle, namely the imperative of performing adequately 
powered studies that, on account of the robustness of their results, could benefit society.  
Finally, despite efforts to minimize potential damage, the research area is of such a nature 
that discomfort cannot be ruled out completely. However, the current project’s potential 
moral, practical and socials benefits are believed to outweigh possible disadvantages.  
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8 CONCLUSIONS 
The association between suicide and use of psychotropic medications is neither novel, nor 
surprising, since the majority of people who take their lives suffer from psychiatric disorders. 
The use of pharmacological treatment and other psychiatric and social interventions is 
widespread, yet the assessment of suicide risk is complex. Neurobiological postmortem 
findings in suicide overlap with current models of psychotropic functioning, yet the specific 
mechanisms underlying suicide are still largely unknown. With the exception of clozapine 
and lithium, evidence for psychotropic medications conferring antisuicidal or prosuicidal 
effects remains inconclusive. Previous scholarship has not been able to explain whether 
initiation of treatment transiently increases the risk of suicide; whether the purchasing 
behavior of subjects without dispensed prescriptions in part reflects undertreated depression; 
or how often patients, having filled a prescription, actually take their medications. 
In the papers in this thesis, by way of postmortem toxicological verification of exposure to 
prescribed psychotropic medications, we have investigated the association between SSRI 
treatment and violent suicide; adherence to common non-addictive psychotropics in the 
general population; differences in psychotropic purchasing behavior; and the extent to which 
incomplete adherence to treatment with psychotropics affects the risk of completed suicide. 
Based on the results of this thesis, the following conclusions are drawn:  
1. Treatment with SSRIs seems to influence the choice of suicide method during early 
treatment, particularly among elderly subjects. This effect is confounded by the use of 
other substances (including other medications and illegal drugs). A likely reason for this 
association is latency to onset of antidepressive effect, but it is still unclear how such 
latency specifically influences the ultimate method of suicide.   
2. Adherence to psychotropics at therapeutic levels in the general population is higher than 
what would be expected from previous research and highest among subjects treated with 
antidepressants. Postmortem toxicological detectability of medications is influenced by a 
number of factors, including unconventional dosing and biological half-lives. 
3. Adherent users of antipsychotics carry a lower risk for completed suicide compared to 
partially and non-adherent users. Results regarding suicide risks conferred by incomplete 
adherence to antidepressants remain inconclusive. The ratio of initiated to discontinued 
dispensations of psychotropic medications increases markedly among suicide victims 
compared to non-suicide deaths during the months prior to death, indicating a possible 
operationalizable measure of continued need of treatment and severity of suicidality.  
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9 IMPLICATIONS FOR THE FUTURE 
9.1 CLINICAL IMPLICATIONS 
Our findings indicate that users of SSRIs during early treatment run an increased risk of 
choosing a violent suicide method, and thereby an increased risk of suicide completion. 
However, we do not yet know whether this risk is part of an ongoing suicidal process, 
including previous and escalating attempts, or a newly initiated behavior. Given that SSRI 
treatment is an important therapeutic option for a rather wide range of psychiatric disorders, 
ongoing treatment should not be discontinued, nor initiation of treatment delayed, based on 
our findings.  
Although our results indicate a higher than expected level of adherence to psychotropic 
medications in the general population, a large rate of non-adherence was nonetheless 
uncovered, not least among users of antipsychotics. Given that we have shown that partial 
and complete non-adherence increase suicide risk in this group, clinical efforts aimed at 
improving adherence – such as patient education, increased frequency of clinical visits, 
measurements of blood concentrations of prescribed antipsychotics and social support – 
should also prevent suicide.  
Furthermore, our results indicate that violent suicidality may be counteracted by adherent 
antipsychotic use, although its general antisuicidal effect is yet to be investigated. 
Nevertheless, when other forms of treatment for suicidality have failed, antipsychotics should 
be tried, not least since adherence to antipsychotics may be ensured through the use of long-
acting injectables. 
Finally, changes in dispensations of psychotropic medications that are indicative of switching 
and increased polypharmacy could possibly be implemented as a warning sign, in response to 
which the threshold for inpatient care might be lowered to prevent suicidal behavior. 
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9.2 FUTURE PERSPECTIVES 
In the course of this doctoral project, several questions have emerged that merit further 
research. 
A general antisuicidal effect of antipsychotics? 
In the light of our findings, further research is called for to investigate the possible general 
antisuicidal effects of antipsychotic medications, especially with regard to treatment with 
long-acting injectables. In addition, it is of importance to assess how regimes combining 
antidepressant and antipsychotic medications affect suicide risk. 
Pharmacogenomics and adherence 
Pharmacogenetic testing may serve as a tool to provide information about the likelihood of 
adverse responses to a medication that could jeopardize adherence, increasing the risk of 
suicide. 
Hair analyses in toxicological pharmacoepidemiology  
Postmortem blood sampling provides detailed information concerning substance use, but 
forensic sampling is most often restricted to single instances of cross-sectional sampling. 
Through the use of toxicological hair analyses, several time periods of substance use and non-
use may be uncovered across a span of time, allowing longitudinal assessments and 
speculations concerning causality. In addition, through the use of this approach, exclusion of 
cases of non-violent suicide resulting from intoxication can be avoided. 
Extended use of the dispensation ratio 
The dispensation ratio has thus far only been used to analyze violent completed suicide. The 
method is, however, suited for a range of outcomes and could possibly be integrated into 
automated prospective studies of pharmacovigilance.  
Other sources of outpatient data in suicide research 
In an attempt to distinguish violent behavior as a side effect of psychotropic treatment from 
confounding by indication, real-world historical outpatient information concerning 
aggression, violence and type of suicidality prior to initiated psychotropic therapy could be 
studied. Registries of interest in this regard include the Stockholm County Council Outpatient 
Registry, the Criminal Records Registry and the Records of Suspected Offenders Registry. 
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10 POPULÄRVETENSKAPLIG SVENSK 
SAMMANFATTNING 
Det fullbordade självmordet är ett komplext fenomen som har kopplats till ett stort antal 
riskfaktorer. Psykisk sjukdom medför en av de högsta riskerna för självmord och är mål för 
läkemedelsbehandling i bland annat suicidpreventivt syfte. Läkemedels självmordsskyddande 
effekt har emellertid varit svår att utvärdera och ytterligare kunskap om behandlingsformens 
möjliga roll i suicidprocessen är av stor vikt. 
Avhandlingens syfte har varit att fokusera på biokemisk bekräftelse av läkemedelsbehandling 
bland individer i Sverige som avlidit i självmord eller av andra orsaker. Vi har undersökt 
antidepressiva läkemedels (SSRI, selektiva serotoninåterupptagningshämmare) roll vid val av 
självmordsmetod samt åskådliggjort graden av följsamhet till psykofarmaka i den svenska 
befolkningen. I en ännu opublicerad studie har vi därtill undersökt mönster av receptuttag 
före död samt till vilken grad läkemedelsföljsamhet påverkar risken för fullbordat självmord.  
Studierna i avhandlingen har baserats på svenska registerdata från nära ett decennium (2005-
2014) med heltäckande information rörande uthämtade läkemedelsrecept, rättsmedicinska 
obduktionsresultat och registrerade diagnoser i samband med sjukhusvistelser. 
Läkemedelsföljsamhet har värderats genom jämförelse mellan uthämtade läkemedelsrecept 
och fynd av läkemedel i blod vid dödstillfället. Genom att jämföra andelen påbörjade och 
avslutade läkemedelsbehandlingar har vi därtill utvecklat ett mått på sjukdomsgrad.  
Våra fynd pekar på att SSRI-behandling kan kopplas till val av våldsam självmordsmetod i 
tidig behandling hos äldre. Vidare har vi klargjort att andra substanser (läkemedel och illegala 
preparat) är en viktig påverkande faktor vid utvärdering av SSRI-läkemedels inverkan vid val 
av självmordsmetod. Följsamhet till icke beroendeframkallande psykofarmaka i den svenska 
befolkningen har vi visat vara överlag god. Slutligen ger våra resultat bevis på att bristande 
följsamhet till psykosdämpande läkemedel är kopplad till en tydlig förhöjd risk för fullbordat 
självmord. 
Sammanfattningsvis, genom att kombinera rättsmedicinska analyser med svenska nationella 
registerdata, har vi visat på läkemedels möjliga inverkan vid självmord. Fynden är av värde 
för framtida självmordsförebyggande arbete och belyser att resultat från rättsmedicinska 
obduktioner även kan komma till nytta för en bredare allmänhet. 
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